Introduction {#s1}
============

Interruption of regional blood flow within the brain can rapidly cause irreparable neuronal damage. The cerebral circulation exhibits unique capabilities that allows it to adjust to varying environmental conditions and pathophysiological situations so as to maintain optimal perfusion and minimize such injury. G-protein-coupled receptors and ion channels present on the endothelial cells and vascular smooth muscle cells (SMCs) that form the walls of cerebral blood vessels initiate many of the signaling cascades that enable these intrinsic adaptive processes. The specific cellular pathways responsible for cerebrovascular homeostasis are of considerable interest as potential therapeutic targets for diseases associated with impaired blood flow regulation within the brain, such as stroke and vascular cognitive impairment; however, these pathways remain incompletely understood. We recently reported that transient receptor potential ankyrin 1 (TRPA1) cation channels are present in the endothelium of arteries within the brain, but not in other arterial beds ([@bib51]), suggesting a specialized role for these channels in cerebral blood flow regulation. In the current study, we investigated the endogenous adaptive and protective functions of TRPA1 channels within the cerebral vasculature.

TRPA1, the sole member of the mammalian ankyrin TRP subfamily, is a large-conductance, Ca^2+^-permeable, non-selective cation channel ([@bib37]; [@bib14]; [@bib20]). TRPA1 channels are present on perivascular nerves surrounding small mesenteric arteries, and their stimulation causes vasodilation through release of C-protein gene-related peptide ([@bib3]). In addition, TRPA1 channels form a Ca^2+^-signaling complex with intermediate-conductance, Ca^2+^-activated potassium channels (K~Ca~3.1) at sites of close contact between cerebral artery endothelial cells and underlying SMCs ([@bib12]). Consequently, activation of TRPA1 channels, for example with the electrophilic compound allyl isothiocyanate (AITC), derived from mustard oil, induces endothelium-dependent vasodilation of cerebral resistance arteries, an effect that is prevented by blockade of K~Ca~3.1 channels ([@bib12]). Endogenous regulation of TRPA1 in the cerebral endothelium has been linked to reactive oxygen species (ROS), particularly superoxide anions (O~2~^-^) generated by NADPH oxidase 2 (NOX2) ([@bib51]). ROS-induced activation of TRPA1 has been shown to occur through a process that requires generation of lipid peroxidation products that directly activate the channel, such as 4-hydroxynonenal (4-HNE) ([@bib51]; [@bib55]). Increased generation of ROS and oxidative stress is a hallmark of vascular diseases, but the importance of TRPA1-mediated vasodilation for the regulation of blood flow in the brain under pathological conditions remains unknown.

Cerebral blood vessels have the inherent ability to dilate in response to hypoxia ([@bib24]). When hypoxia occurs within specific regions of the brain, this adaptation increases localized blood flow to the affected area, enhancing delivery of oxygen. Although the molecular and cellular mechanisms responsible for this important response are not known, a recent study suggested that TRPA1 channels are sensitive to changes in O~2~ concentration and are activated by both hyperoxic and hypoxic conditions ([@bib54]). In addition, hypoxia and ischemia are linked to elevated ROS production and increased generation of 4-HNE ([@bib47]; [@bib25]), an endogenous activator of TRPA1 activity.

Here, we tested the hypothesis that hypoxia causes activation of TRPA1 channels in the cerebral endothelium, resulting in vasodilation, and further propose that this response constitutes an adaptive response during perfusion deficiency. Using an integrative approach and a newly developed mouse model expressing a Ca^2+^ biosensor exclusively in endothelial cells, we elucidated the underlying molecular mechanisms responsible for activation of TRPA1 channels in the intact cerebral endothelium during hypoxia and investigated the pathophysiological impact of this novel pathway in vivo using an established model of ischemic strokes. Our findings suggest that TRPA1 channels in the cerebral endothelium are early sensors of hypoxia and initiate an adaptive response to reduce ischemic damage in the brain.

Results {#s2}
=======

New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries {#s2-1}
------------------------------------------------------------------------------------------------------------------------------------------------------

A primary goal of this study was to determine the direct effects of hypoxia on TRPA1 channels that are present in the endothelium of intact cerebral arteries ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). An effective strategy for directly measuring changes in channel activity is to record local, transient elevations in cytosolic Ca^2+^ levels generated by Ca^2+^ influx through single TRPA1 channels in the endothelium, detected as TRPA1 sparklets ([@bib51]), using optical patch-clamp methods ([@bib50]) ([Figure 1A](#fig1){ref-type="fig"}). A previous study reported the use of transgenic mice expressing the *Gcamp2* Ca^2+^ biosensor under the control of the Cx40 promoter to record TRPV4 sparklets in the endothelium of mesenteric arteries ([@bib49]). However, we found that the fluorescence intensity of Cx40-based *Gcamp2* (and *Gcamp5*) Ca^2+^ biosensors was very low in the endothelium of cerebral arteries, preventing reliable recordings from being obtained. We also found that the cerebral endothelium could not be effectively loaded with standard Ca^2+^ indicator dyes, such as Fluo-4AM. To overcome these limitations, we generated a new transgenic mouse line that expresses *Gcamp6f*, a Ca^2+^ biosensor with fast kinetics ([@bib7]), exclusively in the endothelium. To accomplish this, we crossed mice heterozygous for the expression of a floxed *Stop* codon upstream of the *Gcamp6f* gene (see Materials and methods) with mice heterozygous for the expression of *cre*-recombinase under the control of the endothelial-specific *Tek* promoter/enhancer (*Tek^cre^*). The *mT/mG* reporter mouse ([@bib36]) was used to confirm that *cre*-recombinase is only expressed in the endothelium of cerebral arteries from *Tek^cre^* mice ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We found that cerebral, mesenteric, skeletal muscle and pulmonary arteries isolated from *Tek:Gcamp6f* mice expressed the Ca^2+^ biosensor only in the endothelium and provided excellent signal-to-noise ratio for optical detection of spontaneous and evoked Ca^2+^ signals in this tissue ([Videos 1](#video1){ref-type="video"}--[4](#video4){ref-type="video"}).

![4-HNE stimulates TRPA1 sparklets in the endothelium of intact cerebral arteries.\
(**A**) Representative images of endothelial cells from cerebral arteries from *Tek:Gcamp6f* mice mounted *en face*, presented in grayscale (left) and pseudocolored (middle and right panels). Scale bar = 15 µm. The images on the right are a timelapse and digital magnification of the TRPA1 sparklet indicated by the arrow in the right and middle panels. Scale bar = 5 µm. (**B**) Representative pseudocolored images of a 512 × 512 pixels field of view from *Tek:Gcamp6f* mice showing sparklets (green) after exposure to vehicle, 4-HNE and 4-HNE + A967079. Scale bar = 20 µm. (**C**) Representative ΔF/F~0~ vs. time plots for a single sparklet site. 0, 1, two levels indicate hypothesized numbers of TRPA1 channels engaged during each signal. (**D**) Summary data showing the effects of the TRPA1 channel activator 4-HNE (1 µM) on TRPA1 sparklet frequency, site frequency and number of sites per cell (n = 24 fields of view from four different arteries, N = 4 mice). (**E**) TRPA1 inhibition with A967079 (1 µM) significantly prevented 4-HNE induction of TRPA1 sparklets in endothelial cells (20 fields of view from five different arteries; N = 3 mice). Data are presented as means ± SEM (\*p\<0.05, *Student*'s t-test). TRPA1 sparklets were recorded in the presence of the cell permeable Ca^2+^ chelator EGTA-AM (10 µM) and the sarcoendoplasmic reticulum Ca^2+^-ATPase inhibitor cyclopiazonic acid (CPA, 30 µM).\
10.7554/eLife.35316.010Figure 1---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 1](#fig1){ref-type="fig"}.](elife-35316-fig1){#fig1}

###### Spontaneous Ca^2+^transients in the endothelium of a cerebral artery.

Representative movie of a cerebral artery from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) without EGTA-AM or CPA.

10.7554/eLife.35316.011

###### Ca^2+^events in the endothelium of a mesenteric artery from a *Tek:Gcamp6f* mouse.

Representative movie of a mesenteric artery from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) without EGTA-AM or CPA.

10.7554/eLife.35316.012

###### Ca^2+^events in the endothelium of a skeletal muscle artery from a *Tek:Gcamp6f* mouse.

Representative movie of an skeletal muscle artery from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) without EGTA-AM or CPA.

10.7554/eLife.35316.013

###### Ca^2+^events in the pulmonary endothelium from a *Tek:Gcamp6f* mouse.

Representative movie of a pulmonary artery from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) without EGTA-AM or CPA.

10.7554/eLife.35316.014

To initially characterize TRPA1 sparklets in the intact cerebral endothelium, we mounted pial arteries from *Tek:Gcamp6f* mice *en face* as previously described ([@bib49]). The endothelium of arteries mounted *en face* is not subjected to physiological levels of luminal shear stress and intraluminal pressure and cannot be used to study how these stimuli affect endothelial cell function. However, Sonkusare *et al.* showed that the TRPV4 sparklets recorded from the endothelium of arteries mounted *en face* are statistically indistinguishable from those recorded from intact arteries pressurized at physiological levels, suggesting that longitudinal incision of the artery does not alter basic ion channel properties ([@bib49]). To isolate Ca^2+^ influx events, we treated initial preparations with the sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase (SERCA) inhibitor cyclopiazonic acid (CPA, 30 μM) to prevent release of Ca^2+^ from intracellular stores. Vessels used for these Ca^2+^ signaling experiments were also treated with the cell-permeant Ca^2+^ chelator EGTA-AM (10 μM) to limit the intracellular diffusion of Ca^2+^ influx and improve the signal-to-noise ratio.

Using these conditions, the endothelium was exposed to a near-maximally effective concentration (1 μM) of the endogenous TRPA1 agonist 4-HNE ([@bib51]) via the superfusing bath. Ca^2+^ events were recorded at an average of \~40 frames/s in a 512 × 512 pixel field of view (pixel size = 0.27 μm) containing approximately 40 endothelial cells (mean area of cerebral artery endothelial cells = 462 ± 24 μm^2^, n = 25 cells, N = 5 mice). We observed that 4-HNE significantly increased the frequency of highly localized, transient Ca^2+^ signals by approximately 10-fold compared with vehicle controls (0.51 ± 0.05 Hz vs. 0.07 ± 0.01 Hz) ([Figure 1D](#fig1){ref-type="fig"} and [Videos 5](#video5){ref-type="video"} and [6](#video6){ref-type="video"}). Notably, these signals exhibited distinct amplitude levels and duration reminiscent of single-channel activity recorded using patch-clamp electrophysiology ([@bib10]) ([Figure 1C](#fig1){ref-type="fig"}). The selective TRPA1 antagonist A967079 (1 μM) ([@bib6]) significantly diminished the 4-HNE--induced increase in activity, reducing the frequency of these Ca^2+^ signals from 0.51 ± 0.06 Hz to 0.06 ± 0.02 Hz ([Figure 1E](#fig1){ref-type="fig"}). The frequency of Ca^2+^ signals induced by exposure to 4-HNE was also significantly reduced by removal of extracellular Ca^2+^, confirming that these signals are generated by an influx of Ca^2+^ ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Collectively, these data identify the local, transient Ca^2+^ signals evoked by administration of 4-HNE as *bona fide* TRPA1 sparklets.

###### Spontaneous Ca^2+^influx events the cerebral endothelium.

Representative movie of a cerebral artery isolated from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) in the presence of EGTA-AM (10 µM) and CPA (30 µM).

10.7554/eLife.35316.015

###### 4-HNE stimulates TRPA1 sparklets the cerebral artery endothelium.

Representative movie of the same field of view as in [Video 5](#video5){ref-type="video"} showing that application of 4-HNE (1 μM) significantly increased the frequency of TRPA1 sparklets in the cerebral endothelium. TRPA1 sparklets were recorded in the presence of EGTA-AM (10 µM) and CPA (30 µM).

10.7554/eLife.35316.016

Further analyses showed that the number of active sites per field of view significantly increased from 1.68 ± 0.27 under control conditions to 4.41 ± 0.52 in the presence of 4-HNE ([Figure 1B and D](#fig1){ref-type="fig"}, data shown as number of sites per cell). In addition, sparklet frequency at existing sites significantly increased from 0.06 ± 0.01 Hz at baseline to 0.13 ± 0.02 Hz following application of 4-HNE ([Figure 1C and D](#fig1){ref-type="fig"}). These findings indicate that the increase in TRPA1 sparklet frequency induced by administration of 4-HNE resulted from both the recruitment of previously inactive sparklet sites as well as an increase in the frequency of previously active sites. TRPA1 inhibition with the selective inhibitor A967079 largely prevented the increases in the number of active sparklets sites as well as the increase in sparklet frequency at previously active sites ([Figure 1B,C and E](#fig1){ref-type="fig"}). A plot of the amplitudes (ΔF/F~0~) of individual TRPA1 sparklets revealed a Gaussian distribution with a mode of 1.10 ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). The mean attack time (half-time to reach peak signal amplitude), decay time (half-time from peak to loss of signal), and duration of mode-amplitude TRPA1 sparklets were 87 ± 7 ms, 84 ± 6 ms, and 373 ± 23 ms, respectively. The mean spatial spread of TRPA1 sparklets was approximately 17.2 ± 0.6 μm^2^, or \~3% of the total surface area of a single endothelial cell in this intact vascular preparation ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

Stimulation of TRPA1 with 4-HNE also increases the frequency of larger Ca^2+^ transients {#s2-2}
----------------------------------------------------------------------------------------

We previously reported that stimulation of TRPA1 channels with the electrophilic compound allyl isothiocyanate (AITC) increased the frequency of dynamic Ca^2+^ release from the ER due to Ca^2+^-induced Ca^2+^ release ([@bib44]). To determine if 4-HNE -stimulated TRPA1 sparklets have a similar effect on ER Ca^2+^ release, we exposed cerebral arteries from *Tek:Gcamp6f* mice mounted *en face* to 4-HNE in the absence of CPA or EGTA-AM. Under these conditions, the frequency of spontaneous transient events was significantly higher compared with arteries treated with CPA and EGTA-AM. 4-HNE significantly increased the frequency of Ca^2+^ transients (0.76 ± 0.08 vs. 2.44 ± 0.20 Hz, [Videos 7](#video7){ref-type="video"} and [8](#video8){ref-type="video"}, [Figure 2C](#fig2){ref-type="fig"}), and this response was blocked by the TRPA1 channel inhibitor A967079 (1.12 ± 0.09 Hz, [Figure 2C](#fig2){ref-type="fig"} and [Video 9](#video9){ref-type="video"}). Spontaneous and 4-HNE-evoked Ca^2+^ transients were not significantly different in amplitude, but were larger in terms of spatial spread and mean duration compared with TRPA1 sparklets ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). The increase in Ca^2+^ transients appeared to be a consequence of recruitment of previously inactive sites (number of sites per cell: 0.26 ± 0.02 vs. 1.44 ± 0.24), as well as an increase in frequency of Ca^2+^ release from previously active sites (0.072 ± 0.004 vs. 0.121 ± 0.005 Hz, [Figure 2A--C](#fig2){ref-type="fig"}). TRPA1 inhibition with A967079 diminished the recruitment of new sites of Ca^2+^ transients (number of sites per cell: 0.29 ± 0.02, [Figure 2A and C](#fig2){ref-type="fig"}) and reduced the frequency of Ca^2+^ transients in previously active sites (0.098 ± 0.003 Hz, [Figure 2B and C](#fig2){ref-type="fig"}). These data suggest that TRPA1 sparklets induce Ca^2+^ release from the ER, thereby amplifying the initial Ca^2+^ influx signal.

![4-HNE stimulates large Ca^2+^transients in the endothelium of intact cerebral arteries.\
(**A**) Representative grayscale images of endothelial cells from *Tek:Gcamp6f* mice mounted *en face* in the absence of CPA and EGTA-AM. The white arrowheads point to sites of Ca^2+^ transients. Scale bar = 30 µm. Pseudocolored representations of the images are shown below. Scale bar = 30 µm. (**B**) Representative ΔF/F~0~ vs. time plots of Ca^2+^ transients from a single site of Ca^2+^ transients. (**C**) Summary graphs showing that 4-HNE (1 µM) significantly increases frequency, number of active sites, and site frequency of Ca^2+^ transients in cerebral artery endothelial cells. This response was diminished by the TRPA1 blocker A967079 (1 µM). (25 fields of view from three different arteries; N = 3 mice). Data are presented as means ± SEM (\*p\<0.05, one-way ANOVA).\
10.7554/eLife.35316.018Figure 2---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 2](#fig2){ref-type="fig"}.](elife-35316-fig2){#fig2}

###### Spontaneous large Ca^2+^transients in the endothelium of a cerebral artery.

Representative movie of a cerebral artery from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) without EGTA-AM or CPA.

10.7554/eLife.35316.019

###### 4-HNE increases the frequency of Ca^2+^transients in the cerebral artery endothelium.

Representative movie of the same field of view as in [Video 7](#video7){ref-type="video"} showing that 4-HNE (1 µM) greatly increases the frequency of Ca^2+^ transients in the endothelium. Events were recorded in the absence of EGTA-AM or CPA (30 µM).

10.7554/eLife.35316.020

###### TRPA1 channels mediate the increase in Ca^2+^transients caused by 4-HNE.

Representative movie of the same field of view as in [Videos 7](#video7){ref-type="video"} and [8](#video8){ref-type="video"} showing that TRPA1 inhibition with A967079 (1 µM) prevents the increase in Ca^2+^ transients frequency elicited by 4-HNE (1 µM) in the endothelium. TRPA1 sparklets were recorded in the presence of EGTA-AM (10 µM) and CPA (30 µM).

10.7554/eLife.35316.021

Hypoxia induces accumulation of 4-HNE and increases TRPA1 sparklet frequency in the endothelium of intact cerebral arteries {#s2-3}
---------------------------------------------------------------------------------------------------------------------------

To test the hypothesis that hypoxia induces production of 4-HNE in the endothelium, *en face* cerebral arteries were incubated in normoxic or hypoxic conditions. Hypoxia was achieved by superfusing the tissue with physiological saline solution (PSS) equilibrated with a hypoxic gas mixture (5% O~2~, 6% CO~2~, 89% N~2~). The *pO~2~* measured in the recording bath under these conditions was 13 ± 2 mmHg (n = 5). The pH of the superfusing solution was monitored in real time, and was constantly maintained between 7.37 and 7.42 during normoxic and hypoxic conditions. We observed an increase in 4-HNE immunolabeling in cerebral arteries superfused with hypoxic PSS when compared to arteries superfused with normoxic PSS ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

![Acute hypoxia increases 4-HNE accumulation and increases TRPA1 sparklet frequency in the cerebral endothelium.\
(**A**) Representative maximum intensity projection of Z-stacks of cerebral arteries mounted *en face and* exposed to PSS equilibrated with a normoxic (21% O~2~, 6% CO~2~, 73% N~2~, left panel) or hypoxic gas mixture (5% O~2~, 6% CO~2~, 89% N~2~, right panel) and immunolabeled for 4-HNE (red). Scale bar = 40 µm, nuclei of cells are labeled by DAPI (blue). Acute hypoxia significantly increased 4-HNE immunoreactivity in cerebral arteries (\*p\<0.05 *Student*'s t-test, N = 10--9 fields of view from three different experiments). (**B**) Representative pseudocolored images of cerebral arteries from *Tek:Gcamp6f* mice mounted *en face* and exposed to normoxic (left panel) or hypoxic (middle and right panels) PSS in the presence or absence of the selective TRPA1 blocker A967079 (1 µM). Green: active TRPA1 sparklet sites. Scale bar = 20 µm. (**C**) Representative ΔF/F~0~ vs. time plots for a single sparklet site showing an increase in TRPA1 sparklet frequency during hypoxia which was significantly inhibited by the TRPA1 blocker A967079. (**D**) Summary data showing the effects of hypoxia on TRPA1 sparklet frequency (left), site frequency (middle) and number of sites per cell (right) in the presence and absence of the selective TRPA1 inhibitor A967079 (1 µM). (\*p\<0.05, one-way ANOVA; N = 25--28 -- 33 fields of view from six different arteries isolated from six mice). TRPA1 sparklets were recorded in the presence EGTA-AM (10 µM) and CPA (30 µM).\
10.7554/eLife.35316.027Figure 3---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 3](#fig3){ref-type="fig"}.](elife-35316-fig3){#fig3}

Arteries from *Tek:Gcamp6f* mice were used to test the hypothesis that acute hypoxic exposure acts through TRPA1 channels to increase the frequency of Ca^2+^ influx events in the cerebral endothelium. Acute hypoxic exposure significantly increased the frequency of TRPA1 sparklets, a response that was significantly reduced by A967079 ([Figure 3B--3D](#fig3){ref-type="fig"} and [Videos 10](#video10){ref-type="video"} and [11](#video11){ref-type="video"}). The increase in TRPA1 sparklet frequency induced by hypoxia reflected an increase in the number of active sparklets sites ([Figure 3B and D](#fig3){ref-type="fig"}) as well as the frequency of sparklets at active sites (control, 0.049 ± 0.007 Hz; hypoxia, 0.089 ± 0.007 Hz; p\<0.05, [Figure 3C and D](#fig3){ref-type="fig"}); both increases were prevented by the TRPA1 inhibitor A967079, which restored TRPA1 sparklet frequency to levels that were not significantly different from normoxic conditions (0.057 ± 0.007 Hz, [Figure 3B](#fig3){ref-type="fig"} -- D). The amplitude, kinetics, and spatial spread of hypoxia-evoked TRPA1 sparklets ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) did not significantly differ from those of 4-HNE--induced TRPA1 sparklets. These data demonstrate that pathophysiologically relevant levels of hypoxia acutely stimulate TRPA1 activity in the endothelium of intact cerebral arteries.

###### Spontaneous Ca^2+^influx events the cerebral endothelium during normoxia.

Representative movie of a cerebral artery isolated from a *Tek:Gcamp6f* mouse mounted *en face* and superfused with normoxic (21% O~2~, 6% CO~2~, 73% N~2~), warm (37°C) physiological saline solution (PSS) in the presence of EGTA-AM (10 µM) and CPA (30 µM).

10.7554/eLife.35316.028

###### Hypoxia stimulates TRPA1 sparklet frequency in the cerebral endothelium.

Representative movie of the same field of view from [Video 10](#video10){ref-type="video"} showing that superfusing the preparation with hypoxic (5% O~2~, 6% CO~2~, 89% N~2~), warm (37°C) physiological saline solution (PSS) increases the frequency and number of active sites of TRPA1 sparklets. TRPA1 sparklets were recorded in the presence of EGTA-AM (10 µM) and CPA (30 µM).

10.7554/eLife.35316.029

Hypoxia-induced increases in mitochondrial ROS stimulate TRPA1 activity in the cerebral endothelium {#s2-4}
---------------------------------------------------------------------------------------------------

We next investigated the molecular mechanisms responsible for activation of TRPA1 channels in endothelial cells during hypoxia. Our prior study demonstrated that extracellular O~2~^-^ generated by NOX2 stimulates the formation of 4-HNE, which in turn activates TRPA1 channels in the cerebral endothelium ([@bib51]). Unexpectedly, we found that extracellular superoxide dismutase (SOD) and the NOX inhibitor apocynin did not significantly inhibit hypoxia-induced increases in TRPA1 sparklet frequency ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting the involvement of an alternative pathway. Consistent with this latter possibility, we found that hypoxia-induced increases in TRPA1 sparklet frequency and sites per cell were significantly reduced by membrane-permeant PEG-SOD, suggesting that intracellular generation of ROS is essential for this response ([Figure 4B](#fig4){ref-type="fig"}). This conclusion is supported by imaging experiments showing that hypoxia caused a time-dependent increase in the fluorescence intensity of the ROS indicator dihydroethidium (DHE) in freshly isolated cerebral artery endothelial cells, which was prevented by PEG-SOD ([Figure 4A](#fig4){ref-type="fig"}).

![Acute hypoxia induces mitochondrial superoxide generation and increases TRPA1 sparklet frequency in the cerebral endothelium.\
(**A**) *Left and middle:* Superoxide generation detected with the superoxide-sensitive dye DHE (red) in the endothelium of cerebral arteries mounted *en face* under normoxia (left), hypoxia (left), hypoxia plus the membrane-permeable PEG-SOD (100 U/ml, middle) and hypoxia plus the mitochondria-targeted SOD mimetic mitoTEMPO (500 nM, middle). *Right:* Summary data showing changes in DHE fluorescence over time under each condition (\*p\<0.05, two-way ANOVA; n = 5--7 -- 6--7 arteries from five different mice). The arrow in the graph indicates the onset of hypoxia. Scale bar = 10 µm. (**B and C**) Summary data showing the effects of PEG-SOD (**B**) and mitoTEMPO (**C**) on the frequency and number of active TRPA1 sparklet sites in the cerebral artery endothelium of *Tek:Gcamp6f* mice (\*p\<0.05, *Student*'s t-test; n = 25--30 fields of view from six different preparations isolated from six different mice). TRPA1 sparklets were recorded in the presence of EGTA-AM (10 µM) and (CPA, 30 µM).\
10.7554/eLife.35316.033Figure 4---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 4](#fig4){ref-type="fig"}.](elife-35316-fig4){#fig4}

Having eliminated NOX as a potential source of increased ROS production during hypoxia, we investigated the involvement of other pathways. A previous study suggested that generation of ROS by mitochondrial respiration is increased during hypoxia ([@bib16]). In agreement with this report, we found that pre-incubation of freshly isolated endothelial cells with the mitochondrial-targeted antioxidant mitoTEMPO (500 nM) significantly inhibited hypoxia-induced increases in DHE fluorescence ([Figure 4A](#fig4){ref-type="fig"}), suggesting that mitochondria are the primary source of intracellular ROS generated during hypoxia. To determine if mitochondrial ROS are responsible for the activation of TRPA1 channels during hypoxia, we treated cerebral arteries from *Tek:Gcamp6f* mice with mitoTEMPO prior to hypoxia exposure. This treatment significantly diminished hypoxia-induced increases in TRPA1 sparklet frequency, indicating a critical role for mitochondrial ROS generation in this response ([Figure 4C](#fig4){ref-type="fig"}).

Hypoxia dilates cerebral pial arteries and penetrating arterioles by activating TRPA1 channels in the endothelium {#s2-5}
-----------------------------------------------------------------------------------------------------------------

Pressure myography studies using intact cerebral pial arteries were carried out to study the influence of TRPA1 channels on hypoxia-induced dilation. Arteries were pressurized to physiological levels (60 mmHg) and allowed to generate spontaneous myogenic tone. Acute exposure to hypoxia (*pO~2~* = 13 ± 2 mmHg) induced vasodilation that was significantly diminished by disruption of endothelial cell function by passing an air bubble through the vascular lumen ([@bib45]) ([Figure 5A](#fig5){ref-type="fig"}), indicating involvement of the endothelium. Vasodilation in response to hypoxia was also inhibited by Tempol (100 µM) ([Figure 5B](#fig5){ref-type="fig"}), but was not significantly reduced by NOX2 inhibition and extracellular SOD ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), supporting the concept that intracellular ROS generation is required for this response. Further, we found that hypoxia-induced dilation was significantly blunted by mitoTEMPO (500 nM) ([Figure 5C](#fig5){ref-type="fig"}), suggesting that mitochondria are the source of ROS required for this response. Control experiments showed that Tempol and mitoTEMPO had no significant effect on cerebral artery dilation in response to administration of 4-HNE, indicating that these drugs do not directly inhibit this TRPA1-dependent response ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

![Hypoxia acts *via* mitochondrial superoxide to induce endothelium-dependent dilation of pressurized cerebral arteries.\
(**A**) Representative traces (left) and summary data (right) showing hypoxia-induced dilation in intact and endothelium-denuded cerebral pial arteries (\*p\<0.05, *Student*'s t-test; n = 5 arteries from three different mice). (**B**) Representative traces of lumen diameter of a pressurized cerebral pial artery (left) and summary data (right) showing hypoxia-induced dilation in the presence of the cell-permeant SOD mimetic Tempol (100 µM). (\*p\<0.05, *Student*'s t-test; n = 5 arteries from three different mice.) (**C**) Representative traces of the lumen diameter of a pressurized cerebral pial artery (left) and summary data (right) showing hypoxia-induced dilation in the presence of the cell-permeant mitochondrial membrane-targeted SOD mimetic mitoTEMPO (500 nM). (\*p\<0.05, *Student*'s t-test; n = 6 arteries from three different mice). The arteries used for pressure myography experiments were not treated with EGTA-AM or CPA.\
10.7554/eLife.35316.039Figure 5---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 5](#fig5){ref-type="fig"}.](elife-35316-fig5){#fig5}

Vasodilation in response to hypoxic exposure was significantly reduced by blockade of TRPA1 channels with A967079 ([Figure 6A](#fig6){ref-type="fig"}) and was diminished in cerebral arteries isolated from endothelial cell-specific TRPA1 knockout mice (*Trpa1* ecKO) ([@bib51]) compared with TRPA1 floxed, cre-recombinase negative, littermate controls (*Trpa1^fl/fl^*, [Figure 6B](#fig6){ref-type="fig"}). To investigate potential vasodilator mechanisms acting downstream of TRPA1 channels, we blocked K~Ca~3.1 channels with TRAM34 and K~Ca~2.3 channels with apamin. This treatment significantly reduced hypoxia-induced dilation ([Figure 6C](#fig6){ref-type="fig"}). Together, these data demonstrate that hypoxia-induced increases in mitochondrial ROS production stimulate TRPA1-mediated Ca^2+^ influx in the cerebral artery endothelium, causing vasodilation of pial arteries through activation of K~Ca~3.1 and/or K~Ca~2.3 channels.

![Hypoxia-induced cerebral artery dilation is dependent on endothelial TRPA1, K~Ca~3.1 and K~Ca~2.3 channels.\
(**A**) Representative traces of luminal diameter of pressurized cerebral pial arteries (left) and summary data (right) showing hypoxia-induced dilation in the presence and absence of the selective TRPA1 inhibitor A967079 (\*p\<0.05, *Student*'s t-test; n = 5 arteries from three different mice). (**B**) Representative traces of the luminal diameter of pressurized cerebral pial arteries (left) and summary data (right) showing hypoxia-induced dilation in *Trpa1* ecKO mice and wildtype littermates (*Trpa1^fl/fl^*) (\*p\<0.05, *Student*'s t-test; n = 7--6 arteries from three different mice). (**C**) Representative traces of the luminal diameter of pressurized cerebral pial arteries (left) and summary data (right) showing hypoxia-induced dilation in the presence of selective inhibitors of K~Ca~3.1 (TRAM34, 1 µM) and K~Ca~2.3 channels (apamin, 1 µM) (\*p\<0.05, *Student*'s t-test; n = 5 arteries from three different mice). The arteries used for pressure myography experiments were not treated with EGTA-AM or CPA.\
10.7554/eLife.35316.041Figure 6---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 6](#fig6){ref-type="fig"}.](elife-35316-fig6){#fig6}

We also investigated the effects of TRPA1 activity on vasomotor activity of cerebral penetrating arterioles. Brain slices (200 µm in thickness) from perfusion-fixed *Tek^gfp^ mice* (Tg(TIE2GFP)287Sato/J) reporter mice that express GFP in the endothelium ([@bib35]) were immunolabeled for TRPA1. Penetrating arterioles were identified as branches from the surface pial arteries that entered the underlying brain parenchyma. TRPA1 immunofluorescence was detected in the endothelium of penetrating arterioles ([Figure 7A](#fig7){ref-type="fig"}, left panels, red) but was not detected when the primary antibody for TRPA1 was omitted, although GFP fluorescence was observed ([Figure 7A](#fig7){ref-type="fig"}, right panels). Functional ex vivo pressure myography experiments showed that exposing penetrating arterioles to 4-HNE induced dilation that was significantly diminished by A967079 ([Figure 7B](#fig7){ref-type="fig"}). In addition, exposure of pressurized penetrating arterioles to hypoxia caused dilation that was blunted by A967079 ([Figure 7C](#fig7){ref-type="fig"}). Together, these data suggest that TRPA1 channels are present and functional in penetrating arterioles and elicit vasodilation in response to 4-HNE and hypoxia.

![TRPA1 channel activity dilates cerebral penetrating arterioles.\
(**A**) Representative maximum intensity projection laser scanning confocal images showing immunolabeling of TRPA1 channels (red) in EGFP-expressing endothelial cells (green) of penetrating arterioles in the brain (left panels, primary present). Scale bar = 20 µm. TRPA1 immunoreactivity was absent when the primary antibody was omitted (right panels). Nuclei of cells were stained by DAPI (blue). Scale bar = 20 µm. (**B**) Incubation of ex vivo pressurized penetrating arterioles with the TRPA1 agonist 4-HNE (1 µM) induced arteriolar dilation which was significantly diminished by A967079 (1 µM). Representative traces are shown on the left and the summary graph is shown on the right. (\*p\<0.05, *Student*'s t-test; n = 5 arteries from three different mice). (**C**) Hypoxia induced dilation of penetrating arterioles that was significantly blunted by A967079 (\*p\<0.05, *Student*'s t-test; n = 6 arteries from three different mice). The arterioles used for pressure myography experiments were not incubated with EGTA-AM or CPA.\
10.7554/eLife.35316.043Figure 7---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 7](#fig7){ref-type="fig"}.](elife-35316-fig7){#fig7}

Endothelial cell TRPA1 activity decreases damage following ischemic stroke {#s2-6}
--------------------------------------------------------------------------

Our data indicate that hypoxia-induced activation of TRPA1 channels in the endothelium of cerebral arteries and penetrating arterioles causes vasodilation. We propose that hypoxia-induced vasodilation of cerebral arteries is an adaptive response that serves to improve collateral perfusion within affected brain regions following ischemic stroke. To test this hypothesis, we induced ischemic strokes in *Trpa1* ecKO mice and *TRPA1^fl/fl^* control littermates using the middle cerebral artery occlusion (MCAO) model ([@bib30]) without reperfusion. We found that although reduction in cerebral perfusion after MCAO did not significantly differ between *Trpa1^fl/fl^* and *Trpa1* ecKO mice ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), infarct size was significantly increased in *Trpa1* ecKO mice compared with littermate controls 24 hr after MCAO ([Figure 8A](#fig8){ref-type="fig"}). In companion interventional studies, we examined the effects of stimulating TRPA1 activity with cinnamaldehyde (CinA) after MCAO. Using pressure myography, we found that CinA induced a concentration-dependent dilation of pressurized cerebral arteries isolated from control mice, a response that was absent in cerebral arteries isolated from *Trpa1* ecKO mice ([Figure 8---figure supplement 2A and B](#fig8s2){ref-type="fig"}). CinA (30 µM) also induced dilation of penetrating arterioles, a response that was significantly blunted by A967079 ([Figure 8---figure supplement 2C and D](#fig8s2){ref-type="fig"}). Pharmacological activation of TRPA1 channels in vivo by intraperitoneal (i.p.) injection of CinA (50 mg/kg) ([@bib19]), administered 15 min after MCAO, significantly reduced infarct size in control C57/bl6 mice ([Figure 8B](#fig8){ref-type="fig"}). This protective effect of CinA is partially dependent on endothelial cell TRPA1 channels as infarct size in *Trpa1* ecKO mice was not significantly reduced by CinA ([Figure 8C](#fig8){ref-type="fig"}). These data suggest that the endogenous activity of TRPA1 channels in the cerebral endothelium reduces cerebral damage associated with ischemic strokes.

![Endothelial cell TRPA1 channel activity protects against ischemic strokes.\
(**A**) Representative photographs of brain slices (left) and summary data (right) showing significantly greater ischemic damage 24 hr after MCAO in *Trpa1* ecKO mice compared with *Trpa1^fl/fl^*. Brain slices were stained with 2,3,5-triphenyltetrazolium chloride (TTC), which stains metabolically active tissue red, whereas infarcted tissue remains unstained (white). Infarcted areas were quantified and expressed as a percentage of total hemisphere area (\*p\<0.05, *Student*'s t-test; n = 5--5 mice). (**B**) Representative photographs of brain slices (left) and summary data (right) showing reduced cerebral ischemic damage in wildtype C57/bl6 mice treated with the TRPA1 channel activator cinnamaldehyde (CinA, 50 mg/kg i.p.), injected 15 min after MCAO (\*p\<0.05 for CinA vs. vehicle, *Student*'s t-test; n = 5--6 mice). (**C**) Representative photographs of brain slices (left) and summary data (right) showing that the protective effects of CinA were blunted in *Trpa1* ecKO mice (\*p\<0.05 for CinA-treated *Trpa1* ecKO mice vs. CinA-treated *Trpa1^fl/fl^* mice, *Student*'s t-test; n = 6--5 mice). Legends for Supplemental Figures.\
10.7554/eLife.35316.050Figure 8---source data 1.Excel spreadsheet containing the individual numeric values of the parameters analyzed in [Figure 8](#fig8){ref-type="fig"}.](elife-35316-fig8){#fig8}

Discussion {#s3}
==========

In this study, we investigated the functional importance of TRPA1 channels in the cerebral endothelium under pathophysiological conditions. We found that acute hypoxic exposure induced an increase in TRPA1 sparklet frequency in the endothelium of intact cerebral pial arteries and penetrating arterioles that caused dilation. Pharmacological activation of TRPA1 in vivo reduced the loss of brain tissue in response to experimentally induced ischemic stroke, whereas conditional knockout of TRPA1 in the endothelium exacerbated this damage ([Figure 8---figure supplement 3](#fig8s3){ref-type="fig"}). We propose that TRPA1 activity is important in mediating hypoxia-induced dilation of the cerebral vasculature during ischemic stroke, and that this response improves collateral blood flow to the affected region to improve outcomes.

TRPA1 channels are activated by electrophilic compounds, such as AITC, allicin and CinA, which target specific cysteine residues located in the cytosolic pre-S1 domain linking the channel's ankyrin-repeat region to the first membrane-spanning domain ([@bib17]; [@bib33]; [@bib38]). In addition, considerable evidence demonstrates that TRPA1 channels are activated by ROS and/or ROS-derived metabolites ([@bib51]; [@bib55]; [@bib42]). Lipid peroxidation products such as 4-HNE and related substances appear to act on the same cysteine residues that are targeted by electrophilic molecules ([@bib17]; [@bib33]; [@bib42]), providing evidence for a common mechanism of activation. It has been suggested that TRPA1 channels are activated by hypoxia, such as reported by Takahashi *et al.,* who showed that shifting *pO~2~* from 150 mmHg to 80 mmHg stimulated TRPA1 activity, measured using the FLIPPER assay in HEK cells overexpressing TRPA1. The authors interpreted this finding as evidence of hypoxia-induced activation of TRPA1. However, under normal physiological conditions in healthy humans, the *pO~2~* of arterial blood is \~80--100 mmHg within the aorta,\~30--70 mmHg in capillaries, and \~20--40 mmHg in the venous system ([@bib56]). Viewed in this context, the data reported by Takahashi *et al*. appear to suggest that TRPA1 channels are activated by restoration of normoxia following hyperoxic exposure, rather than by hypoxia per se. In our study, the *pO~2~* of the superfusing bath was closely monitored and was maintained at \~80--90 mmHg during control (normoxic) conditions and determined to be \~13 mmHg during acute hypoxic challenge. TRPA1 activity, detected as TRPA1 sparklets, was low under normoxic conditions, but was stimulated by change to a hypoxic *pO~2~*. It should be noted that the *pO~2~* in the rat brain following an ischemic stroke varies from near anoxia in the infarct core (\~1--2 mmHg) to \~10--15 mmHg in the peri-infarct area ([@bib29]) --- values of *pO~2~* similar to those observed in our tissue bath experiments. Thus, our data suggest that pathophysiologically relevant levels of hypoxia acutely activate TRPA1 channels in the intact cerebral endothelium.

In a prior study, we showed that extracellular O~2~^-^ generated by NOX2 activates TRPA1 channels in the cerebral endothelium through a process that requires lipid peroxidation ([@bib51]). However, here we found that hypoxia-induced activation of TRPA1 was independent of both NOX activity and extracellular O~2~^-^. Instead, we found that intracellular generation of O~2~^-^ was required for hypoxia-induced activation of TRPA1. Previous reports have shown that acute hypoxic exposure uncouples the mitochondrial electron transport chain ([@bib23]), stimulating a localized burst of O~2~^-^ ([@bib16]), which can enter the cytoplasm through anion channels present in the mitochondrial outer membrane ([@bib15]). In agreement with earlier reports showing that hypoxia increases mitochondrial O~2~^-^ production in cancer cells ([@bib5]; [@bib46]; [@bib11]) and cultured endothelial cells ([@bib16]), we found that exposure to acute hypoxia stimulated ROS generation in native cerebral artery endothelial cells, and that this response was inhibited by a mitochondrial-targeted SOD mimetic and by intracellular PEG-SOD. A recent study reported that mitochondria are located at the base of myoendothelial projections ([@bib31]), which are regions of near contact between the plasma membrane of endothelial cells and the underlying smooth muscle cells. TRPA1 channels are also concentrated within myoendothelial projection ([@bib51]; [@bib12]). Thus, it is possible that hypoxia-induced increases in mitochondria O~2~^-^ production generates 4-HNE within myoendothelial projections, leading to TRPA1 activation in those sites. Our data provide support for a signaling pathway initiated by mitochondrial-generated O~2~^-^, showing that these superoxide ions stimulate the activity of TRPA1 channels in the cerebral endothelium during acute hypoxic exposure. The current studies do not specifically establish whether mitochondrial O~2~^-^ activates TRPA1 channels directly or if activation requires lipid peroxidation.

TRPA1 channels conduct mixed cation currents with a large Ca^2+^ fraction ([@bib20]; [@bib57]), and activation of TRPA1 on the plasma membrane of endothelial cells transiently creates small microdomains with high localized Ca^2+^ concentrations ([@bib51]). Our prior studies demonstrated that TRPA1-mediated Ca^2+^ influx stimulated by direct application of AITC ([@bib12]) or through O~2~^-^ generated by NOX2 (1) triggers endothelium-dependent dilation of cerebral arteries, a response that is unaffected by blocking nitric oxide synthase or cyclooxygenase pathways, but is sensitive to inhibition of Ca^2+^-activated K~Ca~3.1 and K~Ca~2.3 K^+^ channels. TRPA1 channels and K~Ca~3.1 channels co-localize within myoendothelial projections ([@bib12]), such that influx of Ca^2+^ though TRPA1 channels within these spatially restricted regions is sufficient to increase the local \[Ca^2+^\] to levels capable of activating outward K^+^ currents through K~Ca~3.1 and K~Ca~2.3, leading to hyperpolarization of the endothelial cell plasma membrane ([@bib51]; [@bib12]). Hyperpolarization of the endothelial cell plasma membrane, in turn, is conducted to SMCs through myoendothelial gap junctions, resulting in relaxation and vasodilation ([@bib48]; [@bib4]). In addition, TRPA1 activation by AITC ([@bib44]) and 4-HNE stimulates Ca^2+^ release from intracellular stores, leading to an increase in Ca^2+^ transients previously linked to activation of K~Ca~3.1 (39). Our current findings show that activity of K~Ca~3.1 and/or K~Ca~2.3 channels is required for cerebral artery dilation in response to hypoxia, suggesting that these channels act downstream of TRPA1 in this setting.

Our data also show that pharmacological inhibition of TRPA1 channels or *Trpa1* knockout in the endothelium did not completely abolish hypoxia-induced dilation of cerebral arteries and arterioles, suggesting the possibility that redundant or overlapping mechanisms contribute to this response. Several possibilities have been reported, including endogenous generation of carbon monoxide ([@bib27]) and TRPV3 channel activity. TRPV3 has been shown to be sensitized by acute hypoxia in a ROS-independent manner ([@bib21]), and cause endothelium-dependent dilation of cerebral pial arteries and penetrating arterioles in response to chemical agonists ([@bib40]; [@bib13]).

Ischemic stroke is one of the leading causes of death and disability worldwide. The extent of neuronal loss following an ischemic insult is determined in part by the supply of blood to the region surrounding the infarct core, known as the ischemic penumbra ([@bib32]; [@bib18]). The penumbra is characterized by structurally intact, but metabolic silent, parenchymal tissue in which perfusion is impaired ([@bib53]). Increasing blood flow to the ischemic penumbra has been shown to reduce expansion of the infarct zone and, consequently, improve neurological outcomes ([@bib8]). Our findings suggest that activation of TRPA1 channels in endothelial cells of cerebral arteries is an early adaptive response to acute reduction in tissue *pO~2~*, leading to a possible increase in perfusion within the penumbra. Loss of TRPA1 signaling in endothelial cells of cerebral arteries increased cerebral infarcts following permanent middle cerebral artery occlusion in mice. Further, pharmacological activation of TRPA1 decreased infarcts, an effect blunted by loss of endothelial TRPA1 channels. Isoflurane, the anesthetic agent used during MCAO surgeries, was previously shown to potentiate TRPA1 activity ([@bib34]). Interestingly, isoflurane anesthesia is neuroprotective in various animal models of stroke and subarachnoid hemorrhage ([@bib1]; [@bib2]; [@bib28]; [@bib22]), but the mechanistic basis of this effect is not known. The current findings support the concept that isoflurane may provide neuroprotection by potentiating TRPA1-mediated cerebral arterial dilation.

In summary, the present study shows that hypoxia stimulates Ca^2+^ influx through TRPA1 channels in the intact cerebral endothelium *via* a mechanism that requires generation of intracellular O~2~^-^ by mitochondria. We also demonstrated that hypoxia-induced TRPA1 activity initiates endothelium-dependent dilation of cerebral pial arteries and penetrating arterioles. Selective deletion of TRPA1 expression in the endothelium exacerbated the loss of brain tissue associated with ischemic stroke, providing evidence that hypoxia-induced activation of TRPA1 in the cerebral endothelium constitutes a novel adaptive response.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation               Source or reference       Identifiers            Additional information
  (species) or resource                                                                              
  ----------------------- ------------------------- ------------------------- ---------------------- -----------------------------------
   strain, strain\        *Tek^cre^*                Jackson Laboratories;\    stock \# 008863        
  background\                                       PMID: 11161575                                   
  (*Mus musculus*),\                                                                                 
  C57bl6                                                                                             

   strain, strain\        *mT/mG*                   Jackson Laboratories;\    stock \# 007676        
  background\                                       PMID: 17868096                                   
  (*Mus musculus*),\                                                                                 
  C57bl6                                                                                             

   strain, strain\        *Tek^gfp^*                Jackson Laboratories;\    stock \# 003658        
  background\                                       PMID: 11064424                                   
  (*Mus musculus*),\                                                                                 
  C57bl6                                                                                             

   strain, strain\        *Gcamp6f*                 Jackson Laboratories;\    stock \# 028865        
  background\                                       PMID: 25741722                                   
  (*Mus musculus*),\                                                                                 
  C57bl6                                                                                             

   strain, strain\        *Trpa1 ecKO*              Other; PMID: 25564678     NA                     Mice with endothelium-specific\
  background\                                                                                        deletion of Trpa1. We\
  (*Mus musculus*),\                                                                                 have characterized these\
  C57bl6                                                                                             mice in a previous\
                                                                                                     publication (PMID: 25564678).

   strain, strain\        *Tek:Gcamp6f*             This paper                NA                     Mice expressing the fast\
  background\                                                                                        kinetics, genetically encoded\
  (*Mus musculus*),\                                                                                 Ca^2+^ biosensor *Gcamp6f*\
  C57bl6                                                                                             exclusively in endothelial cells.

   antibody               anti-4-HNE\               Abcam                     ab46545                1:1000 dilution
                          (rabbit polyclonal)                                                        

   antibody               anti-TRPA1\               Alomone Labs;\            ACC-037                1:1000 dilution
                          (rabbit polyclonal)       UniProtKB - O75762\                              
                                                    (TRPA1_HUMAN)                                    

   antibody               anti-GFP\                 Abcam; UniProtKB\         ab5450                 1:500 dilution
                          (goat polyclonal)         - P42212 (GFP_AEQVI)                             

   antibody               Alexa 488 or 594\         ThermoFisher Scientific   A11055 (Alexa 488);\   1:1000 (Alexa 488);\
                          secondaries                                         A21207 (Alexa 594)     1:2000 (Alexa 594)

   other                  Isolectin GS-IB~4~\       ThermoFisher Scientific   I21411                 1:1000 dilution
                          conjugated to Alexa 488                                                    

   other                  dyhydroethidium           ThermoFisher Scientific   D11347                 

   other                  Fluoroshied mounting\     Abcam                     ab104139               
                          medium with DAPI                                                           

   software, algorithm    SparkAn                   Dr. Adrian Bonev and\     NA                     Software to analyze Ca^2+^\
                                                    Dr. Mark Nelson;\                                events. Kindly provided\
                                                    PMID: 22095728                                   by Dr. Adrian Bonev and\
                                                                                                     Dr. Mark Nelson from\
                                                                                                     the University of Vermont.
  --------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Adult male and female mice (12--16 weeks of age) were used for all experiments. All animal procedures used in this study were approved by the Institutional Animal Care and Use Committee of the University of Nevada, Reno School of Medicine, and are in accordance with the National Institutes of Health 'Guide for the Care and Use of Laboratory Animals', eigth edition.

### Tek:Gcamp6f mice {#s4-1-1}

Endothelial cell-specific expression of the fast kinetics, genetically encoded Ca^2+^ biosensor *Gcamp6f* ([@bib7]) in mice was achieved by crossing mice heterozygous for expression of a floxed *Stop* codon upstream of the *Gcamp6f* gene (Jackson Labs, stock number: 028865) with mice heterozygous for the expression of *cre* recombinase under the control of the endothelial-specific *Tek* promoter/enhancer (*Tek^cre^*; Jackson Labs, stock number: 008863). We designated this strain *Tek:Gcamp6f*. We confirmed that *cre*-recombinase is only expressed in the endothelium of cerebral arteries of *Tek^cre^* mice by crossing them with the reporter strain *mT/mG* mice (Jackson Labs, stock number: 007676). *mT/mG* mice have loxP sites flanking the genetic sequence for the red fluorescent protein *Tomato* and a *Stop* codon; the genetic sequence for the green fluorescent protein *Egfp* is located downstream from the second loxP site (see diagram in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Thus, expression of *cre*-recombinase removes the sequence for *Tomato* and the *Stop* codon, leading to Egfp production in that particular cell type ([@bib36]). Using this reporter strain, we observed that only endothelial cells expressed Egfp, whereas the underlying smooth muscle layer expressed the red fluorescent protein Tomato ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

### Trpa1 ecKO mice {#s4-1-2}

Endothelial cell-specific deletion of Trpa1 was achieved by crossing mice homozygous for floxed Trpa1 channels containing loxP sites flanking S5/S6 transmembrane domains (Jackson Labs, stock number: 008654) with heterozygous *Tek^cre^* mice, to generate *Trpa1* ecKO mice, as we have previously described ([@bib51]). Mice homozygous for floxed Trpa1, but without expression of cre-recombinase (*Trpa1^fl/fl^*) were used as controls for all experiments.

Recording and analysis of TRPA1 sparklets {#s4-2}
-----------------------------------------

For isolation of cerebral arteries, mice were deeply anesthetized with 4% isoflurane and euthanized by decapitation and exsanguination. The skull was carefully removed and the brain with the brainstem intact was placed in ice-cold tissue collection solution consisting of (in mM) 140 NaCl, 5 KCl, 2 MgCl~2~, 10 dextrose, 10 HEPES (pH 7.4), without Ca^2+^, supplemented with 1% bovine serum albumin (BSA). Cerebral pial arteries were carefully removed from the brain and cleaned of meningeal membranes. Ca^2+^ imaging was performed on cerebral arteries isolated from *Tek:Gcamp6f* mice mounted *en face*. Arteries were opened longitudinally using fine spring scissors (Fine Science Tools, Foster, CA) and mounted on a Sylgard pad using insect pins with the endothelium facing up as previously described ([@bib49]; [@bib26]). The tissue was stretched to its in vivo length and maintained in Ca^2+^-free PSS containing the membrane-permeable Ca^2+^ chelator EGTA-AM (10 μM, ThermoFisher Scientific, Eugene, OR) at 37°C for 15 min, then washed with warm (37°C) Ca^2+^ PSS consisting of (in mM): 119 NaCl, 4.7 KCl, 21 NaHCO~3~, 1.18 KH~2~PO4, 1.17 MgSO~4~, four dextrose, and 1.8 CaCl~2~. The solution was continuously aerated with a normoxic gas mixture (21% O~2~, 6% CO~2~, 73% N~2~) to maintain a constant pH of 7.38--7.42 and *pO~2~* of \~80 mmHg. The pH was continuously measured with an in-line flow-through pH mini-electrode, and solution oxygenation was assessed using an in-line oxygen microelectrode (both from Microelectrodes, Inc., Bedford, NH). ER Ca^2+^ stores were depleted by treating the preparation with the SERCA inhibitor CPA (30 μM; Tocris Biosciences, Bristol, UK) to eliminate Ca^2+^ signals generated by spontaneous ER Ca^2+^ release. CPA was maintained in the bath solution throughout the experiment. All pharmacological agents (4-HNE, A967079, PEG-SOD, mitoTEMPO, extracellular SOD and apocynin) were administered via the superfusing bath solution. Hypoxia was induced by superfusing the tissue with PSS aerated with a hypoxic gas mixture (5% O~2~, 6% CO~2~, 89% N~2~). The *pO~2~* of this solution was 13 ± 2 mmHg, and the pH in the recording chamber was 7.3--7.42. Ca^2+^ images were obtained using an inverted microscope (Olympus iX81; Olympus Corp., Tokyo, Japan), modified to allow imaging in the upright configuration (LSM Tech, Etters, PA) and equipped with epifluorescence illumination, a 60x water-immersion objective (numerical aperture 1.0), and a highly sensitive iXon Ultra EMCCD camera (Andor Technology, Belfast, Northern Ireland). Each field of view was 512 × 512 pixels (one pixel = 0.27 μm), and images were recorded at a rate of 30--55 frames/s for a total of 1000 frames. The duration of each recording was 20--30 s. A separate cohort of *Tek:Gcamp6f mice* were used to assess the effects of 4-HNE on Ca^2+^ signaling activity in the cerebral endothelium in the absence of EGTA-AM and CPA.

Recordings were analyzed using custom software (SparkAn, kindly provided by Drs. Adrian Bonev and Mark T. Nelson, University of Vermont, Burlington Vermont) ([@bib9]). An average of the first 10 images of each recording obtained prior to stimulation was used to define baseline fluorescence (F~0~). TRPA1 sparklets were identified as localized increases in fluorescence (ΔF) within a small region of interest (5.3 × 5.3 μm) after subtraction of F~0~, and manifested as quantal events with characteristic step-wise peaks in plots of fluorescence intensity over time. The frequency of Ca^2+^ signals with amplitude between 1.08 and 1.1 ΔF/F~0~ (and multiples) is reported. Each peak was analyzed individually, and amplitude, attack time (half-time elapsed from the beginning of the event to the peak), decay time (half-time elapsed from the peak to dissipation of the event), duration (total open time of the channel, calculated as \[attack + decay\] x 2), and spatial spread of the Ca^2+^ signal were determined.

Immunofluorescence labeling {#s4-3}
---------------------------

Accumulation of 4-HNE in cerebral arteries exposed to hypoxia was assessed by immunofluorescence labeling. Freshly isolated cerebral arteries were mounted *en face* as described above, and superfused with normoxic or hypoxic PSS for 15 min. The preparations were then fixed with 4% formaldehyde in PBS for 10 min and incubated in 5% BSA +0.1% Triton X-100 for 2 hr at room temperature. Preparations were then incubated with a rabbit polyclonal antibody against 4-HNE (1:1000, Abcam PLC, Cambridge, United Kingdom) overnight. Preparations were washed with PBS and incubated with a donkey anti-rabbit secondary antibody conjugated to AlexaFluor 568 (1:2000, Thermo Fisher Scientific) diluted in 2% BSA +0.1% Triton X-100 for 90 min at room temperature. Preparations were then washed with PBS and incubated with the endothelial cell-labeling isolectin GS-IB4 conjugated to AlexaFluor 488 (1:1000 in PBS, Thermo Fisher Scientific) for 10 min at room temperature. Preparations were washed and mounted in glass slides with coverslips and fluorescence analyzed by laser scanning confocal microscopy in an Olympus FluoView confocal microscope within the same day. Images were obtained in a field of view of 800 × 800 pixels using a 60x oil immersion objective (numerical aperture: 1.42) and a Z-stack spanning the entire thickness of the cerebral artery, from the adventitia to the endothelial cell layer. In order to perform the semi-quantitative assessment of 4-HNE fluorescence, settings (PMT sensitivity, gain and laser power) were adjusted for normoxic cerebral arteries, and the same settings were used for cerebral arteries exposed to hypoxia. Quantification of fluorescence intensity was performed by plotting a Z-axis profile on ImageJ to obtain a fluorescence intensity curve, and the area under the curve was calculated to best represent fluorescence intensity of the entire thickness of the preparation.

A separate group of mice were used to determine if TRPA1 channels are present in penetrating arterioles in the brain. Endothelial cell reporter mice constitutively expressing GFP under the control of the Tek promoter (*Tek^gfp^*, Jackson labs, stock number 003658) were perfusion-fixed with 4% formaldehyde in PBS and the brain was removed from the skull for histological processing. Brain slices (200 µm thick) were acquired using a Leica VT 1200S vibratome (Leica Biosystems GmbH, Wetzlar, Germany) and permeabilized with 0.1% Triton-X in PBS for 2 hr at room temperature. Slices were then incubated in 10% normal horse serum +0.1% Triton-X in PBS for 2 hr at room temperature, followed by incubation with the primary antibodies rabbit anti-TRPA1 (1:1000, Alomone Labs, Jerusalem, Israel) and goat anti-GFP (1:500, Abcam) dissolved in blocking solution overnight at room temperature on a shaker. Controls lacking TRPA1 primary antibody were incubated with anti-GFP alone overnight. Slices were washed with PBS 3 times for 10 min each, then incubated with a donkey anti-rabbit conjugated with AlexaFluor 594 (1:2000, Thermo Fisher Scientific) and a donkey anti-goat conjugated with AlexaFluor 488 (1:1000, Thermo Fisher Scientific) for 2 hr at room temperature on a shaker. Slices were washed three times with PBS and mounted on glass slides using a Fluoroshield Mounting Medium with DAPI (Abcam). Fluorescence images were taken by an Olympus FluoView laser scanning confocal microscope using a 60x oil-immersion objective (numerical aperture: 1.42) in a 1024 × 1024 pixels per field of view. The pixel size was maintained constant at X = 180 nM, Y = 180 nM, Z = 0.801 nM. Z-stacks were captured (\~40 µm in thickness) to allow for 3-dimensional reconstruction of the arteriolar bed.

ROS imaging {#s4-4}
-----------

Superoxide production by native cerebral artery endothelial cells was assessed by confocal imaging of cells stained with the ROS-sensitive dye dyhydroethidium (DHE) ([@bib39]). Native endothelial cells were isolated by dissecting cerebral arteries and incubating them in tissue collection solution supplemented with 1 mg/mL papain (Worthington Biochemical Company, Lakewood, NJ), 1 mg/mL DL-dithiothreitol and 10 mg/mL BSA for 12 min in a 37°C water bath. Arteries were then washed three times with Ca^2+^-free PSS and incubated in tissue-collection solution supplemented with 1 mg/mL type II collagenase (Worthington Biochemical Company) for 12 min in a 37°C water bath. Thereafter, arteries were washed three times with PSS and triturated by passing the solution through a fire-polished glass Pasteur pipette, as described previously ([@bib40]; [@bib43]). Dissociated cells in the solution were placed in a 35 mm glass-bottom dish (Greiner Bio-One GmBH, Germany) and allowed to adhere to the dish for 30 min in a cell culture incubator. After incubating cells with 5 µM DHE (ThermoFisher) for 5 min at 37°C, the culture dish was transferred to a spinning-disk confocal microscope for real-time recordings of fluorescence intensity. Attached cells in the dish were exposed to normoxic or hypoxic PSS supplemented with DHE (5 µM) in cells pre-incubated with vehicle, PEG-SOD (30 min prior to recording) or mitoTEMPO (15 min prior to recording) and recorded at a rate of 1 frame/min for 10 min. Recordings were performed in an Olympus IX-71 microscope coupled to a Yokogawa CSU22 Confocal Scanning Unit (Yokogawa Electric Corporation, Tokyo, Japan) and an Andor iXon + camera (Andor Technology) using a 100x oil-immersion objective (numerical aperture 1.45). Cells were excited using a 488 nm laser and emission was detected using a 500--530 band-pass emission filter.

Pressure myography {#s4-5}
------------------

The effect of hypoxia on the diameters of isolated intact cerebral pial resistance arteries was assessed using pressure myography. Cerebral arteries were carefully dissected and cannulated between two glass cannulas in a pressure myograph chamber (Living Systems Instrumentation, St. Albans, VT). Arteries were pressurized to 60 mmHg and maintained in normoxic PSS at 37°C for 30 min to reach equilibration. Luminal diameter was continuously recorded by edge-detection using videomicroscopy. The viability of each preparation was established by briefly incubating arteries in isotonic PSS containing high extracellular K^+^ (60 mM KCl, 59 mM NaCl; all other components held constant) to induce constriction. Afterwards, arteries were washed with normoxic PSS until spontaneous myogenic tone was generated. Myogenic tone (%) was calculated as \[1 -- (active luminal diameter/passive luminal diameter)\] x 100. Arteries were then exposed to hypoxic PSS for 10 min and subsequently returned to normoxic PSS. All pharmacological experiments were performed in a paired fashion. Passive diameter at 60 mmHg was determined by incubating arteries in Ca^2+^-free PSS supplemented with EGTA (2 mM) and diltiazem (10 μM). In a subset of experiments, the endothelium was removed by passing an air bubble through the lumen of the artery ([@bib45]). This method of endothelium removal was shown to almost completely ablate endothelium-dependent responses, without damaging the underlying smooth muscle cell layer ([@bib45]).

The effects of TRPA1 agonists and hypoxia were also assessed in freshly isolated cerebral penetrating arterioles. Isolation of penetrating arterioles was performed as previously described ([@bib41]). Briefly, penetrating arterioles branching out of the middle cerebral artery were carefully isolated from the surrounding parenchyma and mounted onto glass cannulas in a blind-sac experimental configuration. Penetrating arterioles were pressurized to 40 mmHg and superfused with artificial cerebrospinal fluid (aCSF, in mM: 124 NaCl, 3 KCl, 2 CaCl~2~, 2 MgCl~2~, 1.25 NaH~2~PO~4~, 26 NaHCO~3~, four glucose, pH 7.4). Arteriolar viability was assessed by exposing the preparation to isotonic aCSF containing high extracellular K^+^ (in mM: 67 NaCl, 60 KCl, all other salts remain the same concentration). Viable arterioles were washed with regular aCSF and allowed to generate spontaneous myogenic tone, after which they were exposed to 4-HNE, hypoxia or CinA in the presence or absence of the TRPA1 inhibitor A967079.

Middle cerebral artery occlusion model {#s4-6}
--------------------------------------

Permanent cerebral ischemia was induced using the intraluminal suture model of MCAO ([@bib30]), modified for mice. Mice were initially anesthetized with 2% isoflurane in oxygen and their body temperature was maintained at 37°C. An incision was made at the top of the head for attachment of a laser Doppler flow probe (Periflux System 5000; Perimed AB, Järfälla, Sweden) to measure blood flow to the region supplied by the MCA (5 mm lateral and 1 mm posterior to the bregma). A midline incision was made at the neck to expose the carotid artery, and the lingual, thyroid and external carotid arteries were tied off. A 6--0 nylon monofilament with a rounded silicone tip (Doccol Corporation, Sharon, MA),\~210 μm in diameter, was inserted into the common carotid artery and advanced through the internal carotid artery to block the MCA where it branches from the circle of Willis. MCAO was verified by a sharp drop in blood perfusion, as measured by laser Doppler flowmetry. Mice that showed less than an 80% drop in perfusion were excluded from the study. Ischemia was maintained for 24 hr, after which mice were anesthetized and euthanized by decapitation. A subset of mice was injected with CinA (50 mg/kg body weight \[[@bib19]\]) or an equal volume of vehicle (0.2--0.3 ml of DMSO) 15 min after MCAO to assess the effects of pharmacological activation of TRPA1 on ischemic stroke outcome.

Measurement of infarct size {#s4-7}
---------------------------

The brain was removed from the skull and sliced into 1 mm-thick sections. Ischemic damage was assessed by subsequently staining sections for 20 min with 2% 2,3,5-triphenyltetrazolium chloride, which stains viable tissue red, leaving infarcted tissue white. Brain slices were fixed in 4% formaldehyde in PBS, and digital images were taken. The percentage of infarction was determined using the following equation: %HI = \[(VCVL)/VC\]\*100, where HI is the hemisphere infarcted, VC is the volume of normal tissue in the non-ischemic hemisphere, and VL is the volume of normal tissue in the ischemic hemisphere ([@bib52]).

Chemicals {#s4-8}
---------

Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich Corporation (St. Louis, MO).

Statistical analysis {#s4-9}
--------------------

All summary data are expressed as means ± SEM. Statistical analyses were performed and graphs were constructed using Prism 6.0 (GraphPad Software, Inc., La Jolla, CA). The significance of differences between two groups was tested by paired or unpaired two-tailed Student's t-test, depending on the experimental design. Data that did not fit a normal distribution were tested using a non-parametric alternative. Comparisons of three or more groups were tested by one-way analysis of variance (ANOVA) with a Sidak *post hoc* test. Values of p\<0.05 were considered statistically significant for all experiments.

Sample size for experiments were determined by performing a 2-sided power analysis to reach a power of 0.8 for a value of α ≤0.05. Using these parameters, we determined that Ca^2+^ imaging experiments should have a minimum of 16 field of views; experiments assessing 4-HNE fluorescence should be 5 field of views; pressure myography experiments should be performed in at least three arteries; MCAO experiments required at least three mice.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Neuroprotective Effects of TRPA1 Channels in the Cerebral Endothelium Following Ischemic Stroke\" for consideration by *eLife*. Your article has been reviewed by Richard Aldrich as the Senior Editor, a Reviewing Editor, and three reviewers. The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. The reviewers have opted to remain anonymous.

This is a potentially highly important paper that shows how oxidative species lead to vasodilation in pial brain vessels and potentially heightens blood flux during stress, injury, and/or hypoxia. While the reviewers found merit to your work, they also note serious complications. These are the essential issues that must be addressed in the text and/or with new data.

Past analysis by the Kleinfeld group and by various computational groups conclude that the bulk of the resistance of the vasculature lies in the capillaries with a smaller fraction in the penetrating arterioles. The current work considers only pial arterioles. At the minimum, it is essential to show that penetrating arterioles contain TRPA1 at densities similar or greater than in the pial arterioles. Ideally, the authors should isolate a pial vessel and show that these vessels also react to activation of TRPA1 by 4-HNE.

The reviewers raised many essential points. All the points listed below need to be addressed. The following are deemed essential and must be addressed with new text or additional experiments.

Essential revisions:

As noted by reviewer \#1

\"... it is therefore essential to carry out.... experiments showing that 4-HNE evokes detectable Ca^2+^ transients, that are mediated by TRPA1, in endothelial cells that have never been exposed to CPA or to EGTA-AM.\"

\"There is an apparent contradiction in Figure 3A. The image shows increased DHE fluorescence with hypoxia, while the graph shows a decrease. Please clarify?

Further to Figure 3A, \"It is essential to add data.... to demonstrate that there is a reduction of the generation of ROS inside the cells, as monitored with DHE, when PEG-SOD was applied.\"

As noted by reviewer \#2

\"\[You\] previously assigned the production of ROS to NADPH oxidase, yet the current work assigns it to mitochondria..... If TRPA1 is localized in endothelial projections near the smooth muscle contact site, how can ROS generated in mitochondria and outside projections, and diffuse to the channel without interacting with other proteins? Is it possible that TRPA1 lies outside the projection in the endothelial body?\" Please clarify.

As noted by reviewer \# 3

\"Injection of CinA reduced the infarct size in control.... mice. It is not clear why they chose this to activate TRPA1 \[as\] there is no information that CinA acts TRPA1 to dilate cerebral arteries. Thus, it is important to see if CinA increases TRPA1 sparklets in wild type control \[mice\] but not in eTRPA1-/- \[mice\].

\"\[The\] authors show that hypoxia produced 4-HNE.... However, it is not clear if 4-HNE contributes to TRPA1 sparklets. Based on the findings in Figure 3, TRPA1 channels were activated by mitochondrial ROS. Thus, it seems that 4-HNE do not have a major role in hypoxia-induced TRPA1 sparklets. Please clarify this issue in the Discussion.

Lastly, please make it clear in the Abstract that you are using isolated vessels for all but the infarct data. \" Mouse model\" is too nebulous a term.

Reviewer \#1:

This paper reports that hypoxia of (pial) arteries leads to the generation of reactive oxygen species such as the lipid peroxide 4-hydroxynonenal (4-HNE), which can activate TRPA1 channels in the endothelial cell surface membrane. These let calcium in, which activates gK(Ca) channels, leading to a K^+^ efflux. This in turn raises \[K\]o around the arteries\' smooth muscle, leading to hyperpolarization (via activity of gKir channels) and relaxation, causing vessel dilation. This is suggested to be protective in MCAO.

Many of the steps are well documented, especially those in which KO of TRPA1 in endothelial cells reduces the effects. However, there is a tendency to assume that pharmacological agents will work \"as stated on the tin\". I have the following issues which need to be resolved before a decision could be made on whether to accept the paper.

1\) Choice of vessels to study. The work is done on pial arteries. The authors wish to imply that the dilation produced by TRPA1 in hypoxia will increase blood flow to the brain. To reach this conclusion it would have to be the case that the pial vessels constitute a significant resistance in the vascular pathway between (say) the circle of Willis (where I assume the blood pressure is constant) and the large veins draining the brain. I question whether this is the case, because the pial vessels have multiple anastomoses (to reduce the decrease of brain blood flow if one of them gets blocked: www.ncbi.nlm.nih.gov/pubmed/16379497, www.ncbi.nlm.nih.gov/pubmed/20616030), and so are expected to have a low resistance. Within the brain parenchyma it is known that it is the capillaries that have the highest resistance (www.ncbi.nlm.nih.gov/pubmed/27780904). Can the authors cite evidence that shows that the pial vessels do have a significant resistance?

2\) If the resistance argument downplays the significance of pial dilation, is there evidence that can be cited to suggest that downstream penetrating arterioles or contractile capillary pericytes also express TRPA1, and so might increase blood flow by the same mechanism?

3\) Use of CPA to block SERCA. I do not understand why SERCA pumps were always blocked with cyclopiazonic acid (CPA) to avoid Ca^2+^ signals from stores, and EGTA-AM was applied. Blocking the SERCA will increase the magnitude of Ca^2+^ transients evoked by TRPA1, since it will reduce removal of Ca^2+^ from the cytoplasm. Lowering the baseline \[Ca^2+^\] with EGTA will also increase fractional \[Ca^2+^\] changes. It is therefore essential to carry out at least some experiments showing that 4-HNE evokes detectable Ca^2+^ transients, that are mediated by TRPA1 (i.e. are blocked by A967079 or TRPA1 KO), in endothelial cells that have never been exposed to CPA or to EGTA-AM.

In addition, the Ca^2+^ response of the ECs to the onset of application of CPA should be shown. Presumably \[Ca^2+^\]cytoplasm rises, but are there then more \"spontaneous\" transients?

I wonder also whether CPA affects TRPA1 either directly or by elevating \[Ca^2+^\]i, as thapsigargin has been shown to do (www.ncbi.nlm.nih.gov/pubmed/18515013). If the authors are using CPA instead of thapsigargin because CPA does not affect TRPA1, then they should provide evidence for this.

4\) Pharmacology for modulating ROS. The authors\' current results disagree with their earlier paper showing a role for NOX2 in generating ROS and 4-HNE (a better explanation of this discrepancy needs to be provided). In this paper they claim that PEG-SOD reduces ROS formation specifically inside the cells. It is essential to add data to Figure 3A showing that there is less ROS generation inside the cells (monitored with DHE) when PEG-SOD was applied. In addition, state for how long the preparation was pre-incubated with the PEG-SOD (and on what time scale it was taken up in previous work) and what pre-incubation time was used for mitoTEMPO.

5\) There is an apparent contradiction in Figure 3A (data for mitoTEMPO). The image shows increased DHE fluorescence with hypoxia, while the graph shows a decrease. What is going on?

6\) Removal of endothelium. How is it known that passing a bubble through the vessel has no effect on smooth muscle cells (give references and discuss at least)? In Figure 4 why is Tempol used instead of the PEG-SOD used earlier?

7\) The preparation. Many experiments are carried out on en face prepared vessels, in which I assume the vessel is cut open so that the endothelial cells can be viewed. It is essential to add a reference to this technique, and a discussion of how this highly invasive procedure may affect Ca^2+^ responses.

\(8\) Anesthesia. Mice were anesthetized with isoflurane, a putative TRPA1 agonist (www.ncbi.nlm.nih.gov/pubmed/18574153; www.ncbi.nlm.nih.gov/pubmed/28320952) which may affect the overall expression and activation of TRPA1, which is prone to change in the presence of agonists (www.ncbi.nlm.nih.gov/pubmed/25265225). This must be discussed.

\(9\) Fluo4-AM is said not to enter ECs in subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries.", yet also in subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries." EGTA-AM does. What is the explanation of the difference? Is there in fact any evidence that the EGTA gets in (e.g. from monitoring \[Ca^2+^\]i)?

Reviewer \#2:

The authors hypothesize that endothelial TRPA1 can be activated by hypoxia-derived ROS, leading to cerebral artery dilation and reduced stroke injury. The authors begin their examination by showing that 4-HNE and hypoxia increase TRPA1 activity as assessed through sparklet production. Next, they show the rise TRPA1 activity was blocked by antioxidants and TRPA1 antagonists. Moving to myography, hypoxia was revealed to dilate cerebral arteries, a response that was again disrupted by antioxidants, TRPA1 blockade and in eTRPA1-/- mice. Finally, the authors then show that diminishing TRPA1 activity increases stroke volume while TRPA1 activation reduced infarcts in wildtype, but not eTRPA1-/- mice. The authors conclude that endothelial TRPA1 channels are sensitive to hypoxia and that their activation not only leads to vasodilation but can reduce the deleterious effects of ischemic damage.

Overall, this is an interesting study and one that ties the activity of a unique TRP channel to the genesis of stroke injury. Clearly, the strength of the study lies in the cellular measurements of TRPA1 activation. The connection between TRPA1 and stroke injury is perhaps less certain but understandable given the biological scale over which the authors are working. The reviewer outlines three major concerns that require clarification. See below.

1\) The first concern is conceptual and centers on the TRPA1 activation by ROS. The authors have previously assigned the production of ROS to NADPH oxidase, yet the current work assigns it to mitochondria. The conceptual issue is this. If TRPA1 is localized in endothelial projections near the smooth muscle contact site, how can ROS generated in mitochondria and outside projections, diffuse to the channel without interacting with other proteins? Is it possible that TRPA1 lies outside the projection in the endothelial body? Clarification in the Discussion section would be warranted.

2\) The second concern centers on Figure 5A. The pattern of injury in control mice is not consistent with occlusion of the middle cerebral artery. The injury pattern in the eTRP-/- mice is more in line with control expectations and with that of Figure 5B and 5C. This concern needs to be addressed.

3\) The n numbers for the main experiments are low (n=4-5) and should be increased to align with generally accepted practice.

*Reviewer \#3:*

Pires and Earley described that TRPA1 channel in endothelial cells of cerebral arteries was activated by hypoxia resulting vasodilation. Hypoxia increased the number of localized Ca^2+^ fluxes through TRPA1 channels called TRPA1 sparklets. These TRPA1 sparklets required mitochondrial ROS but not extracellular O2-. Vasodilation by hypoxia was reduced by blockade or endothelial cell-specific deletion of TRPA1 channels. To investigate functional significance of TRPA1-mediated vasodilation, they assessed the ischemic damage by the middle cerebral artery occlusion (MCAO) and found that the deletion of endothelial TRPA1 channels worsened the damage, while activation of TRPA1 channels reduced the damages, suggesting that importance of TRPA1 activity in cerebral endothelium in ischemic strokes.

This is an interesting paper showing that TRPA1 channels activation during hypoxia may initiate adaptive response to reduce damages by ischemia. More importantly, activation of TRPA1 channels after ischemia may have a beneficial effect on ischemic stroke.

However, there are still major concerns.

1\) Authors show that hypoxia produced 4-HNE, an endogenous ligand for TRPA1 channels. However, it is not clear if 4-HNE contributes to TRPA1 sparklets. Based on the findings in Figure 3, TRPA1 channels were activated by mitochondrial ROS. Thus, it seems that 4-HNE do not have a major role in hypoxia-induced TRPA1 sparklets. Please clarify this.

2\) Injection of cinnamaaldehyde (CinA) reduced the infarct size in control C57Bl6J mice. It is not clear why they chose this to activate TRPA1. Other TRPA1 activators (4-HNE, AITC) are used in this study and previous literature by the authors. It seems that there is no information that CinA act TRPA1 to dilate cerebral arteries. Thus, it is important to see if CinA increases TRPA1 sparklets in wild type control but not in eTRPA1-/-.

3\) MCAO experiments suggest that the deletion of TRPA1 increased infarct size and activation of TRPA1 by CinA reduced infarct size. Authors described that the protective effect of CinA is partially dependent on TRPA1 channels in endothelial cells. However, the authors did not test if CinA fail to reduce infarct size by MCAO in eTRPA1-/-. Also, the authors did not show if CinA reduce infarct size in *TRPA1^fl/fl^* mice. Of course, it may not be appropriate to compare the infarct size between Figure 6A and Figure 6C. But, it is not clear if CinA reduces the infarct size in *TRPA1^fl/fl^*.

4\) ROS imaging data is not convincing. It looks DHE fluorescence brighter with hypoxia plus mitoTEMPO. However, there is a trend of decreasing in the summary data.

5\) Authors propose that TRPA1-mediated vasodilation improve blood flow and outcomes after ischemic stroke based on the results using endothelium specific TRPA1 channel knockouts. In vitro data suggest that TRPA1 activity cause vasodilation. However, authors did not test if TRPA1-channels activity actually improve blood flow in vivo.

6\) CPA was treated in all preparations to detect TRPA1 sparklets. It is not clear if Ca^2+^ flux through TRPA1 channels predominantly contribute to hypoxia-induced vasodilation. The contribution of intracellular Ca^2+^ store should be discussed.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your article \"Neuroprotective Effects of TRPA1 Channels in the Cerebral Endothelium Following Ischemic Stroke\" for consideration by *eLife*. Your article has been reviewed by three highly regarded peer reviewers and the evaluation has been overseen by David Kleinfeld Reviewing Editor and Richard Aldrich as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor. All agree that the revised manuscript is much improved and has \"a certain conceptual appeal\". Some sloppiness in the presentation, particularly regarding the quality of the figures, must be corrected prior to a final decision on the manuscript.

Figures:

Missing scale bars Several are far less than compelling and there is a haphazardness to the data presentation. Scale bars are routinely missing, vasomotor responses are variable and of questionable quality, photomicrographs are difficult to interpret, and the calcium data inconsistent.

Figures 1-6. Specify in each legend whether cyclopiazonic acid (CPA) and/or EGTA-AM has been added to the bath.

Figure 1. References to panels in the text need to be corrected. Label axes in times series in panel C.

Figure 2. Label axes in times series in panel B. Improved portioning of the panel sizes would improve the esthetics.

Figure 3. Define the color scales (blue/red) in panel A. Improved portioning of the panel sizes would improve the esthetics.

Figure 4. Improved portioning of the panel sizes would improve the esthetics.

Figure 5. Label axes to times series (vasodilation) in panels A-C.

Figure 6. Label axes to times series in panels A-C.

Figure 7. Add a label for primary antibody in panel A. TRPA1 (red) signals apparently exist outside of Tek (green) signals in panel A. Add a higher magnification image of the overlap as an insert. Note that plotting the logarithm of the intensity is a means to highlight weak but significant signals.

Text

The manuscript includes a number of absolute statement, such as \"... spatial spread of hypoxia-evoked TRPA1 sparklets were identical to those of....\", \"... NOX inhibitor apocynin had no effect....\", etc. \"Identical\" and \"no\" simply do no exist in experimental evidence. Such statements must be presented in statistical terms, such as your use of \"... significantly diminished....\" with reference to data with error bars.

10.7554/eLife.35316.056

Author response

> This is a potentially highly important paper that shows how oxidative species lead to vasodilation in pial brain vessels and potentially heightens blood flux during stress, injury, and/or hypoxia. While the reviewers found merit to your work, they also note serious complications. These are the essential issues that must be addressed in the text and/or with new data.
>
> Past analysis by the Kleinfeld group and by various computational groups conclude that the bulk of the resistance of the vasculature lies in the capillaries with a smaller fraction in the penetrating arterioles. The current work considers only pial arterioles. At the minimum, it is essential to show that penetrating arterioles contain TRPA1 at densities similar or greater than in the pial arterioles. Ideally, the authors should isolate a pial vessel and show that these vessels also react to activation of TRPA1 by 4-HNE.

We agree that this is an important point, although we also note that older literature maintains that the extracranial and pial arteries provide approximately 50% of overall cerebral vascular resistance(Faraci and Heistad, 1990; Heistad, Marcus and Abboud, 1978). We performed the suggested experiments and the revised manuscript now includes new immunofluorescence images showing that TRPA1 channels are present on endothelial cells within penetrating arterioles (Figure 7). Further, new ex vivo pressure myography experiments demonstrate that 4-HNE, hypoxia, and cinnamaldehyde (CinA) cause dilation of pressurized penetrating arterioles that is blocked by the selective TRPA1 inhibitor A967079 (Figure 7 and Figure 8---figure supplement 2). Taken together, our findings indicate that TRPA1 channels are present and functional in penetrating arterioles and dilate these vessels when activated by chemical agonists and hypoxia. Our data support the possibility that hypoxia-induced activation of TRPA1 causes dilation of pial arteries and penetrating arterioles, which together contribute to cerebral vascular resistance and have an important impact on local hemodynamic control within the brain parenchyma.

> The reviewers raised many essential points. All the points listed below need to be addressed. The following are deemed essential and must be addressed with new text or additional experiments.
>
> Essential revisions:
>
> As noted by reviewer \#1
>
> \"... it is therefore essential to carry out.... experiments showing that 4-HNE evokes detectable Ca^2+^ transients, that are mediated by TRPA1, in endothelial cells that have never been exposed to CPA or to EGTA-AM.\"

A primary goal of this study was to elucidate the effects of hypoxia on Ca^2+^ influx through TRPA1 channels in the endothelium, recorded as TRPA1 sparklets. CPA was used in our initial Ca^2+^ imaging experiments in order to deplete intracellular Ca^2+^ stores and abolish Ca^2+^ release from the ER, thereby isolating Ca^2+^ influx events. EGTA-AM was used for methodological reasons -- in pilot studies, we found that the Ca^2+^ chelator improves signal-to-noise ratio, and Ca^2+^ buffering can theoretically prevent Ca^2+^-dependent channel activation/inactivation. This method of *in situ* visualization of TRP channel sparklets was pioneered by an important study from Dr. Mark Nelson's laboratory investigating TRPV4 sparklets in mesenteric arteries (Sonkusare et al., 2012). We included discussion of these methodological details in the revised manuscript.

We also see merit in the experiments proposed by the reviewer and have performed the recommended studies. These new data show that 4-HNE significantly increases the frequency of Ca^2+^ transients in the absence of CPA and EGTA-AM, and that the selective TRPA1 inhibitor A967079 blocked this response. An analysis of these new data is presented in Figure 2 and Supplemental file 2 of the revised manuscript.

> \"There is an apparent contradiction in Figure 3A. The image shows increased DHE fluorescence with hypoxia, while the graph shows a decrease. Please clarify?

We agree that the images of DHE accumulation in endothelial cells after exposure to hypoxia shown in the original manuscript were not representative of the summary data. Image quality has been improved (Figure 4A of the revised manuscript).

> Further to Figure 3A, \"It is essential to add data.... to demonstrate that there is a reduction of the generation of ROS inside the cells, as monitored with DHE, when PEG-SOD was applied.\"

We agree and performed new experiments as suggested. We find that incubation of endothelial cells with PEG-SOD (100 U/mL) prevented the increase in DHE fluorescence caused by hypoxia in endothelial cells (Figure 4A of the revised manuscript).

> As noted by reviewer \#2
>
> \"\[You\] previously assigned the production of ROS to NADPH oxidase, yet the current work assigns it to mitochondria..... If TRPA1 is localized in endothelial projections near the smooth muscle contact site, how can ROS generated in mitochondria and outside projections, and diffuse to the channel without interacting with other proteins? Is it possible that TRPA1 lies outside the projection in the endothelial body?\" Please clarify.

In our previous study we showed that membrane expression of TRPA1 is enriched within myoendothelial projections and co-localizes with NOX2. We also found that stimulation of NOX2 produced O~2~^-^ that activates the channel through a lipid peroxide product (Sullivan et al., 2017), suggesting that ROS metabolites such as 4-HNE are endogenous activators of TRPA1 in endothelial cells. Interestingly, a recent study from Dr. Donald Welsh's laboratory showed that mitochondria are localized to the base of myoendothelial projections in endothelial cells (Maarouf et al., 2007). Thus, it is possible that mitochondrial O~2~^-^ can also lead to generation of lipid peroxide metabolites within myoendothelial projections, leading to subsequent activation of TRPA1 channels. We also reported in our previous publication and in the current study (Figure 7) that TRPA1 channels are present on the endothelial cell plasma membrane outside of myoendothelial projections. Thus, TRPA1 channels can potentially be activated by ROS generated through multiple intracellular pathways and by extracellular sources. We discuss this concept in the revised manuscript (Discussion section).

> As noted by reviewer \# 3
>
> \"Injection of CinA reduced the infarct size in control.... mice. It is not clear why they chose this to activate TRPA1 \[as\] there is no information that CinA acts TRPA1 to dilate cerebral arteries. Thus, it is important to see if CinA increases TRPA1 sparklets in wild type control \[mice\] but not in eTRPA1-/- \[mice\].

We chose CinA for these studies because this compound has previously been used in vivo at the same dosage used here and was well tolerated by the animals (Huang et al., 2007). To address the reviewer's concern regarding the effects of CinA on cerebral artery diameter, data presented in the revised manuscript show that CinA dilates pressurized pial arteries and penetrating arterioles in ex vivo pressure myography studies (Figure 8---figure supplement 2). This response is blocked by the TRPA1 inhibitor A967079 and is absent in arteries and arterioles isolated from *Trpa1* ecKO mice. These data demonstrate that CinA dilates pial arteries and penetrating arterioles by activating TRPA1 channels in the endothelium. We did not attempt the suggested Ca^2+^ imaging experiments because the pressure myography studies directly address the reviewer's concerns.

> \"\[The\] authors show that hypoxia produced 4-HNE.... However, it is not clear if 4-HNE contributes to TRPA1 sparklets. Based on the findings in Figure 3, TRPA1 channels were activated by mitochondrial ROS. Thus, it seems that 4-HNE do not have a major role in hypoxia-induced TRPA1 sparklets. Please clarify this issue in the Discussion.

Data shown in Figure 4 show that hypoxia causes generation of O~2~^-^ by mitochondria and data shown in Figure 3 show that hypoxia increases generation of 4-HNE in the endothelium. Prior studies indicate that O~2~^-^ generates lipid peroxide products including 4-HNE (for a review, see Esterbauer, Schaur and Zollner, 1991). Since 4-HNE stimulates TRPA1 sparklets (Figure 1), we believe that it is plausible that hypoxia-induced increases in O~2~^-^ production by mitochondria generates 4-HNE to activate TRPA1 channels at the plasma membrane. We agree that our data do not specifically rule out the possibility that mitochondrial O~2~^-^ directly activates TRPA1 channels. This possibility is discussed in the revised manuscript (Discussion section).

> Lastly, please make it clear in the Abstract that you are using isolated vessels for all but the infarct data. \" Mouse model\" is too nebulous a term.

We have clarified this issue in the Abstract.

> Reviewer \#1:
>
> This paper reports that hypoxia of (pial) arteries leads to the generation of reactive oxygen species such as the lipid peroxide 4-hydroxynonenal (4-HNE), which can activate TRPA1 channels in the endothelial cell surface membrane. These let calcium in, which activates gK(Ca) channels, leading to a K^+^ efflux. This in turn raises \[K\]o around the arteries\' smooth muscle, leading to hyperpolarization (via activity of gKir channels) and relaxation, causing vessel dilation. This is suggested to be protective in MCAO.
>
> Many of the steps are well documented, especially those in which KO of TRPA1 in endothelial cells reduces the effects. However, there is a tendency to assume that pharmacological agents will work \"as stated on the tin\". I have the following issues which need to be resolved before a decision could be made on whether to accept the paper.
>
> 1\) Choice of vessels to study. The work is done on pial arteries. The authors wish to imply that the dilation produced by TRPA1 in hypoxia will increase blood flow to the brain. To reach this conclusion it would have to be the case that the pial vessels constitute a significant resistance in the vascular pathway between (say) the circle of Willis (where I assume the blood pressure is constant) and the large veins draining the brain. I question whether this is the case, because the pial vessels have multiple anastomoses (to reduce the decrease of brain blood flow if one of them gets blocked: www.ncbi.nlm.nih.gov/pubmed/16379497, www.ncbi.nlm.nih.gov/pubmed/20616030), and so are expected to have a low resistance. Within the brain parenchyma it is known that it is the capillaries that have the highest resistance (www.ncbi.nlm.nih.gov/pubmed/27780904). Can the authors cite evidence that shows that the pial vessels do have a significant resistance?

We appreciate the reviewer's concerns, although we also note that older literature maintains that the extracranial and pial arteries provide approximately 50% of the total vascular resistance in the cerebral circulation (Faraci and Heistad, 1990; Heistad, Marcus and Abboud, 1978). To further address this issue, the revised manuscript includes new data demonstrating that TRPA1 channels are present on the endothelium of penetrating arterioles and that activation of these channels with chemical agonists or hypoxia induced vasodilation. Our data support the possibility that hypoxia-induced activation of TRPA1 causes dilation of pial arteries and penetrating arterioles, which together contribute to cerebral vascular resistance and have an important impact on local hemodynamic control within the brain parenchyma.

> 2\) If the resistance argument downplays the significance of pial dilation, is there evidence that can be cited to suggest that downstream penetrating arterioles or contractile capillary pericytes also express TRPA1, and so might increase blood flow by the same mechanism?

This concern is addressed by our new data showing that activation of TRPA1 with 4-HNE, hypoxia (Figure 7), and CinA (Figure 8---figure supplement 2) induces dilation of pressurized penetrating arterioles, which is blunted by the TRPA1 inhibitor A967079.

> 3\) Use of CPA to block SERCA. I do not understand why SERCA pumps were always blocked with cyclopiazonic acid (CPA) to avoid Ca^2+^ signals from stores, and EGTA-AM was applied. Blocking the SERCA will increase the magnitude of Ca^2+^ transients evoked by TRPA1, since it will reduce removal of Ca^2+^ from the cytoplasm. Lowering the baseline \[Ca^2+^\] with EGTA will also increase fractional \[Ca^2+^\] changes. It is therefore essential to carry out at least some experiments showing that 4-HNE evokes detectable Ca^2+^ transients, that are mediated by TRPA1 (i.e. are blocked by A967079 or TRPA1 KO), in endothelial cells that have never been exposed to CPA or to EGTA-AM.
>
> In addition, the Ca^2+^ response of the ECs to the onset of application of CPA should be shown. Presumably \[Ca^2+^\]cytoplasm rises, but are there then more \"spontaneous\" transients?

A primary goal of this study was to elucidate the effects of hypoxia on Ca^2+^ influx through TRPA1 channels in the endothelium, recorded as TRPA1 sparklets. CPA was used in our initial Ca^2+^ imaging experiments in order to deplete intracellular Ca^2+^ stores and abolish Ca^2+^ release from the ER, thereby isolating Ca^2+^ influx events. EGTA-AM was used for methodological reasons -- in pilot studies, we found that the Ca^2+^ chelator improves signal-to-noise ratio, and Ca^2+^ buffering can theoretically prevent Ca^2+^-dependent channel activation/inactivation. This method of *in situ* visualization of TRP channel sparklets was pioneered by an important study from Dr. Mark Nelson's laboratory investigating TRPV4 sparklets in mesenteric arteries (Sonkusare et al., 2012). We include discussion of these methodological details in the revised manuscript (subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries").

We also see merit in the experiments proposed by the reviewer and have performed the studies. These new data show that 4-HNE significantly increases the frequency of Ca^2+^ transients in the absence of CPA and EGTA-AM, and that the selective TRPA1 inhibitor A967079 blocked this response. A detailed analysis of these new data is presented in Figure 2 of the revised manuscript.

We did not monitor changes in intracellular Ca^2+^ during initial incubation with CPA in order to minimize bleaching of *GCaMP6f* in the endothelium. We see very little spontaneous Ca^2+^ signaling activity in the unstimulated endothelium after a 15-minute incubation in the presence of CPA (Figure 1), suggesting that the compound does not provoke an increase in spontaneous Ca^2+^ transients. Indeed, we see the opposite and as expected, we see more spontaneous activity in the endothelium of arteries that have not been treated with CPA, likely due to spontaneous Ca^2+^ release from the ER (Figure 2).

> I wonder also whether CPA affects TRPA1 either directly or by elevating \[Ca^2+^\]i, as thapsigargin has been shown to do (www.ncbi.nlm.nih.gov/pubmed/18515013). If the authors are using CPA instead of thapsigargin because CPA does not affect TRPA1, then they should provide evidence for this.

We find no evidence in the literature that CPA directly affects TRPA1 channel activity. Data in the current manuscript show that TRPA1 sparklet frequency is very low in the unstimulated endothelium following treatment with CPA (Figure 1), providing evidence that CPA at the concentration used here has no direct effects on TRPA1 activity. It is also unlikely that an increase in cytosolic \[Ca^2+^\] caused by CPA affects TRPA1 activity in our experiments because our initial studies were performed in cells treated with EGTA-AM to buffer changes in intracellular \[Ca^2+^\].

> 4\) Pharmacology for modulating ROS. The authors\' current results disagree with their earlier paper showing a role for NOX2 in generating ROS and 4-HNE (a better explanation of this discrepancy needs to be provided). In this paper they claim that PEG-SOD reduces ROS formation specifically inside the cells. It is essential to add data to Figure 3A showing that there is less ROS generation inside the cells (monitored with DHE) when PEG-SOD was applied. In addition, state for how long the preparation was pre-incubated with the PEG-SOD (and on what time scale it was taken up in previous work) and what pre-incubation time was used for mitoTEMPO.

In our previous study we showed that membrane expression of TRPA1 is enriched within myoendothelial projections and co-localizes with NOX2. We also found that stimulation of NOX2 produced O~2~^-^ that activates the channel through a lipid peroxide product metabolite (Sullivan et al., 2015), suggesting that lipid peroxide products such as 4-HNE are endogenous activators of TRPA1 in endothelial cells. Interestingly, a recent study from Dr. Donald Welsh's laboratory showed that mitochondria are localized to the base of myoendothelial projections in endothelial cells (Maarouf et al., 2007). Thus, it is possible that mitochondrial O~2~^-^ can also lead to generation of lipid peroxide metabolites within myoendothelial projections, leading to subsequent activation of TRPA1 channels. We also reported in our previous publication and in the current study (Figure 7) that TRPA1 channels are also present on the endothelial cell plasma membrane outside of myoendothelial projections. Thus, TRPA1 channels can potentially be activated by ROS generated through multiple intracellular pathways and by extracellular sources. We discuss this concept in the revised manuscript (Discussion section).

We have also included new data (Figure 4A) in the revised manuscript showing that pre-incubation of cerebral arteries with PEG-SOD (100 U/mL) for 30 minutes prior to the onset of hypoxia prevents hypoxia-induced O~2~^-^ generation in endothelial cells. The PEG-SOD concentration and incubation times were selected based on a previous study from the Lombardi laboratory (Lukaszewicz et al., 2016). We have also stated the incubation time for mitoTEMPO (15 minutes) in the methods section of the revised manuscript (subsection "Immunofluorescence labeling").

> 5\) There is an apparent contradiction in Figure 3A (data for mitoTEMPO). The image shows increased DHE fluorescence with hypoxia, while the graph shows a decrease. What is going on?

We agree that the images of DHE accumulation in endothelial cells after exposure to hypoxia shown in the original manuscript were not representative of the summary data. Image quality has been improved (Figure 4A of the revised manuscript).

> 6\) Removal of endothelium. How is it known that passing a bubble through the vessel has no effect on smooth muscle cells (give references and discuss at least)? In Figure 4 why is Tempol used instead of the PEG-SOD used earlier?

Disruption of the endothelium by passing an air bubble through the lumen is a standard method that was first described in 1989 in a study showing loss of endothelial function without impairing smooth muscle function in skeletal muscle arteries (Ralevic et al., 2012). We cite this study in the revised manuscript. We (and many other laboratories) have used the air bubble technique in many prior studies (for example (Pires et al., 2015; Earley, Gonzales and Crnich, 2009), and did not observe loss of smooth muscle function. All vessels used for the current study maintained their ability to constrict in response to increases in intraluminal pressure following passage of an air bubble through the lumen, indicating that smooth muscle function was intact. We state this in the revised manuscript (subsection "ROS Imaging").

We used Tempol for these experiments rather than PEG-SOD because in our hands Tempol has better solubility in the physiological bathing solutions used for pressure myography experiments.

> 7\) The preparation. Many experiments are carried out on en face prepared vessels, in which I assume the vessel is cut open so that the endothelial cells can be viewed. It is essential to add a reference to this technique, and a discussion of how this highly invasive procedure may affect Ca^2+^ responses.

Arteries mounted in the *en face* configuration have been used in several previous studies investigating subcellular Ca^2+^ signals in the intact endothelium resulting from release of Ca^2+^ from the ER^12^ and Ca^2+^ influx recorded as TRPV4 sparklets (Sonkusare et al., 2012; Hong et el., 2013; Marziano et al., 2017). Importantly, a study by Sonkusare et al., 2012 showed that TRPV4 sparklets in the *en face* preparation are indistinguishable from those in pressurized arteries, suggesting that longitudinal incision of the artery does not significantly affect the function of Ca^2+^ influx channels in the endothelium. We acknowledge that the endothelium of arteries mounted *en face* is not subjected to the effects of intraluminal pressure or to shear stress due to blood flow, and we cannot study how these stimuli impact Ca^2+^ signaling activity using this preparation. We have included additional references describing the en face preparation and discuss the strengths and limitations of the technique in the revised manuscript (subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries").

> \(8\) Anesthesia. Mice were anesthetized with isoflurane, a putative TRPA1 agonist (www.ncbi.nlm.nih.gov/pubmed/18574153; www.ncbi.nlm.nih.gov/pubmed/28320952) which may affect the overall expression and activation of TRPA1, which is prone to change in the presence of agonists (www.ncbi.nlm.nih.gov/pubmed/25265225). This must be discussed.

We agree that this is a very interesting point. Prior studies report that isoflurane anesthesia is neuroprotective in various animal models of stroke and subarachnoid hemorrhage (Altay et al., 2012; Altay et al., 2012; Li et al., 2013; Khatibi at al., 2011), but the mechanistic basis of this effect is not known. Our current findings and the studies cited by the reviewer support the concept that isoflurane may provide neuroprotection by potentiating TRPA1-mediated cerebral arterial dilation. This is discussed in the revised manuscript (Discussion section).

> \(9\) Fluo4-AM is said not to enter ECs in subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries.", yet also in subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries." EGTA-AM does. What is the explanation of the difference? Is there in fact any evidence that the EGTA gets in (e.g. from monitoring \[Ca^2+^\]i)?

In pilot studies, we observed that the signal-to-noise ratio of TRPA1 sparklets recorded from *Tek:Gcamp6f* mice is improved by treating the tissue with EGTA-AM, suggesting that it can get into cells. We include this detail in the revised manuscript (subsection "New genetically encoded Ca^2+^ biosensor mice enable optical recording of single-channel TRPA1 activity in the endothelium of intact cerebral arteries").

> Reviewer \#2:
>
> The authors hypothesize that endothelial TRPA1 can be activated by hypoxia-derived ROS, leading to cerebral artery dilation and reduced stroke injury. The authors begin their examination by showing that 4-HNE and hypoxia increase TRPA1 activity as assessed through sparklet production. Next, they show the rise TRPA1 activity was blocked by antioxidants and TRPA1 antagonists. Moving to myography, hypoxia was revealed to dilate cerebral arteries, a response that was again disrupted by antioxidants, TRPA1 blockade and in eTRPA1-/- mice. Finally, the authors then show that diminishing TRPA1 activity increases stroke volume while TRPA1 activation reduced infarcts in wildtype, but not eTRPA1-/- mice. The authors conclude that endothelial TRPA1 channels are sensitive to hypoxia and that their activation not only leads to vasodilation but can reduce the deleterious effects of ischemic damage.
>
> Overall, this is an interesting study and one that ties the activity of a unique TRP channel to the genesis of stroke injury. Clearly, the strength of the study lies in the cellular measurements of TRPA1 activation. The connection between TRPA1 and stroke injury is perhaps less certain but understandable given the biological scale over which the authors are working. The reviewer outlines three major concerns and four minor issues that require clarification. See below.
>
> 1\) The first concern is conceptual and centers on the TRPA1 activation by ROS. The authors have previously assigned the production of ROS to NADPH oxidase, yet the current work assigns it to mitochondria. The conceptual issue is this. If TRPA1 is localized in endothelial projections near the smooth muscle contact site, how can ROS generated in mitochondria and outside projections, diffuse to the channel without interacting with other proteins? Is it possible that TRPA1 lies outside the projection in the endothelial body? Clarification in the Discussion section would be warranted.

In our previous study we showed that membrane expression of TRPA1 is enriched within myoendothelial projections and co-localizes with NOX2. We also found that stimulation of NOX2 produced O~2~^-^ that activates the channel through a lipid peroxide product metabolite (Sullivan et al., 2016), suggesting that lipid peroxide products such as 4-HNE are endogenous activators of TRPA1 in endothelial cells. Interestingly, a recent study from Dr. Donald Welsh's laboratory showed that mitochondria are localized to the base of myoendothelial projections in endothelial cells^5^. Thus, it is possible that mitochondrial O~2~^-^ can also lead to generation of lipid peroxide metabolites within myoendothelial projections, leading to subsequent activation of TRPA1 channels. We also reported in our previous publication that TRPA1 channels are also present on the endothelial cell plasma membrane outside of myoendothelial projections. Thus, TRPA1 channels can potentially be activated by ROS generated through multiple intracellular pathways and by extracellular sources. We discuss this concept in the revised manuscript (Discussion section).

> 2\) The second concern centers on Figure 5A. The pattern of injury in control mice is not consistent with occlusion of the middle cerebral artery. The injury pattern in the eTRP-/- mice is more in line with control expectations and with that of Figure 5B and 5C. This concern needs to be addressed.

We respectfully disagree with the reviewer, as the cerebral infarct data reported in Figure 8A (previously Figure 6A) for *TRPA1^fl/fl^*mice are not significantly different from the infarct observed in regular C57bl6 mice (Figure 8B, hemisphere infarcted: 44.8 ± 7.1 vs 49.3 ± 4.7, *Trpa1^fl/fl^* vs wildtype C57bl6 mice, p = 0.299). However, the infarct size in *Trpa1* ecKO mice was significantly higher than that from C57bl6 mice (hemisphere infarcted (%): 61.9 ± 3.6, p = 0.036). We have replaced the representative images to better represent the summary data shown in the graphs, as well as to show the similarities and differences between the experiments and genetic backgrounds.

> 3\) The n numbers for the main experiments are low (n=4-5) and should be increased to align with generally accepted practice.

The n values used for the original submission were selected on the basis of power analysis to determine the necessary number of biological replicates to give a generally accepted statistical power of 0.05 for each experiment. However, we acknowledge the reviewer's point and have increased the *n* values for most of our experiments.

> Reviewer \#3:
>
> Pires and Earley described that TRPA1 channel in endothelial cells of cerebral arteries was activated by hypoxia resulting vasodilation. Hypoxia increased the number of localized Ca^2+^ fluxes through TRPA1 channels called TRPA1 sparklets. These TRPA1 sparklets required mitochondrial ROS but not extracellular O2-. Vasodilation by hypoxia was reduced by blockade or endothelial cell-specific deletion of TRPA1 channels. To investigate functional significance of TRPA1-mediated vasodilation, they assessed the ischemic damage by the middle cerebral artery occlusion (MCAO) and found that the deletion of endothelial TRPA1 channels worsened the damage, while activation of TRPA1 channels reduced the damages, suggesting that importance of TRPA1 activity in cerebral endothelium in ischemic strokes.
>
> This is an interesting paper showing that TRPA1 channels activation during hypoxia may initiate adaptive response to reduce damages by ischemia. More importantly, activation of TRPA1 channels after ischemia may have a beneficial effect on ischemic stroke.
>
> However, there are still major concerns.
>
> 1\) Authors show that hypoxia produced 4-HNE, an endogenous ligand for TRPA1 channels. However, it is not clear if 4-HNE contributes to TRPA1 sparklets. Based on the findings in Figure 3, TRPA1 channels were activated by mitochondrial ROS. Thus, it seems that 4-HNE do not have a major role in hypoxia-induced TRPA1 sparklets. Please clarify this.

Data shown in Figure 4 show that hypoxia causes generation of mitochondrial O~2~^-^ and data shown in Figure 3 suggest that hypoxia increases generation of 4-HNE in the endothelium. Prior studies indicate that O~2~^-^ can peroxidize membrane lipids to generate lipid peroxide products including 4-HNE (for a review, see Esterbauer, Schaur and Zollner, 1991). Since 4-HNE stimulates TRPA1 sparklets (Figure 1), we believe that it is plausible that hypoxia increases O~2~^-^ production by the mitochondria to generate 4-HNE and activate TRPA1 channels at the plasma membrane. We agree that our data do not specifically rule out the possibility that mitochondrial O~2~^-^ directly activates TRPA1 channel. This possibility is discussed in the revised manuscript (Discussion section).

> 2\) Injection of cinnamaaldehyde (CinA) reduced the infarct size in control C57Bl6J mice. It is not clear why they chose this to activate TRPA1. Other TRPA1 activators (4-HNE, AITC) are used in this study and previous literature by the authors. It seems that there is no information that CinA act TRPA1 to dilate cerebral arteries. Thus, it is important to see if CinA increases TRPA1 sparklets in wild type control but not in eTRPA1-/-.

We chose CinA for these studies because this compound has previously been used in vivo at the same dosage used here and was well tolerated by the animals (Huang et al., 2007). To address the reviewer's concern regarding the effects of CinA on cerebral artery diameter, data presented in the revised manuscript show that CinA dilates pressurized pial arteries and penetrating arterioles in ex vivo pressure myography studies (Figure 8---figure supplement 2). This response is blocked by the TRPA1 inhibitor A967079 and is absent in arteries and arterioles isolated from *Trpa1* ecKO mice. These data demonstrate that CinA dilates pial arteries and penetrating arterioles by activating TRPA1 channels. We did not attempt the suggested Ca^2+^ imaging experiments because the pressure myography studies directly address the reviewer's concerns.

> 3\) MCAO experiments suggest that the deletion of TRPA1 increased infarct size and activation of TRPA1 by CinA reduced infarct size. Authors described that the protective effect of CinA is partially dependent on TRPA1 channels in endothelial cells. However, the authors did not test if CinA fail to reduce infarct size by MCAO in eTRPA1-/-. Also, the authors did not show if CinA reduce infarct size in TRPA1^fl/fl^ mice. Of course, it may not be appropriate to compare the infarct size between Figure 6A and Figure 6C. But, it is not clear if CinA reduces the infarct size in TRPA1^fl/fl^.

With respect, we disagree with the reviewer's comment. In the original submission we tested the effects of CinA injection in the outcome of MCAO in *Trpa1* ecKO mice (Figure 6C in the original submission, Figure 8C in the revised manuscript). These data show that infarct size was smaller in *Trpa1^fl/fl^* (control) mice treated with CinA when compared *Trpa1* ecKO mice treated with CinA.

> 4\) ROS imaging data is not convincing. It looks DHE fluorescence brighter with hypoxia plus mitoTEMPO. However, there is a trend of decreasing in the summary data.

We agree that the images of DHE accumulation in endothelial cells after exposure to hypoxia shown in the original manuscript were not representative of the summary data. Image quality has been improved.

> 5\) Authors propose that TRPA1-mediated vasodilation improve blood flow and outcomes after ischemic stroke based on the results using endothelium specific TRPA1 channel knockouts. In vitro data suggest that TRPA1 activity cause vasodilation. However, authors did not test if TRPA1-channels activity actually improve blood flow in vivo.

The proposed experiments would best be carried out using fMRI or other advanced in vivo imaging modalities. Unfortunately, the capabilities for these potentially elegant studies are not available at our institution. We agree that the suggested experiments would strengthen our conclusions and hope to collaborate with other investigators to more fully characterize the neuroprotective role of TRPA1 channels in the endothelium in an in vivo setting in future studies.

> 6\) CPA was treated in all preparations to detect TRPA1 sparklets. It is not clear if Ca^2+^ flux through TRPA1 channels predominantly contribute to hypoxia-induced vasodilation. The contribution of intracellular Ca^2+^ store should be discussed.

In a prior publication, we showed that the TRPA1 activator AITC stimulated dynamic Ca^2+^ signaling activity in the intact cerebral endothelium that was the result of Ca^2+^ release from IP~3~ receptors on the ER, and that this response was blocked by inhibition of TRPA1 channels (Qian et al., 2013). New data included in the revised manuscript show that 4-HNE increases Ca^2+^ transient activity in the absence of CPA and this response is prevented by the TRPA1 inhibitor A967079. These findings provide evidence that the initial Ca^2+^ signal resulting from Ca^2+^ influx through TRPA1 channels (TRPA1 sparklets) is amplified by Ca^2+^-induced Ca^2+^ release from proximal IP~3~ receptors. We discuss this concept in the revised manuscript (Discussion section).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The reviewers have discussed the reviews with one another and the Reviewing Editor. All agree that the revised manuscript is much improved and has \"a certain conceptual appeal\". Some sloppiness in the presentation, particularly regarding the quality of the figures, must be corrected prior to a final decision on the manuscript.

All of the Figures have been improved and some of the photomicrographs have been replaced with higher magnification images.

> Figures:
>
> Missing scale bars Several are far less than compelling and there is a haphazardness to the data presentation. Scale bars are routinely missing, vasomotor responses are variable and of questionable quality, photomicrographs are difficult to interpret, and the calcium data inconsistent.
>
> Figures 1-6. Specify in each legend whether cyclopiazonic acid (CPA) and/or EGTA-AM has been added to the bath.

We have included this information in the legend for each main figure and their supplemental figures.

> Figure 1. References to panels in the text need to be corrected. Label axes in times series in panel C.

We corrected references to the figures in the text and we added labels to both the X and Y axes in each of the time series.

> Figure 2. Label axes in times series in panel B. Improved portioning of the panel sizes would improve the esthetics.

We added labels to both the X and Y axes in each of the time series plots in panel B and changed the spatial distribution of the panels to improve esthetics.

> Figure 3. Define the color scales (blue/red) in panel A. Improved portioning of the panel sizes would improve the esthetics.

The color scale in panel A is now defined in the photomicrograph and in the figure legend (blue: DAPI nuclear staining; red: 4-HNE). We improved the portioning of the panels for better esthetics.

> Figure 4. Improved portioning of the panel sizes would improve the esthetics.

We improved the portioning of the panels for better esthetics.

> Figure 5. Label axes to times series (vasodilation) in panels A-C.

We added labels to both the X and Y axes in each of the time series in panels A-C. In addition, we have included several new traces of hypoxia-induced vasodilation to illustrate experimental reproducibility.

> Figure 6. Label axes to times series in panels A-C.

We added labels to both the X and Y axes in each of the time series in panels A-C. We included new traces of hypoxia-induced vasodilation.

> Figure 7. Add a label for primary antibody in panel A. TRPA1 (red) signals apparently exist outside of Tek (green) signals in panel A. Add a higher magnification image of the overlap as an insert. Note that plotting the logarithm of the intensity is a means to highlight weak but significant signals.

We included the label for each primary antibody used in panel A (GFP and TRPA1). The Review Editor points out that TRPA1 seems to be present outside of endothelial cells in our photomicrographs. Astrocytes express TRPA1 channels (Shigetomi et al.,2013; Shigetomi et al., 2011), and it is likely that the signal observed outside of endothelial cells is from TRPA1 channels present in astrocytic end-feet (astrocyte projections that envelop blood vessels within the brain parenchyma). It is important to note that we have not performed co-staining of astrocytes and TRPA1 to confirm this possibility, as this is outside of the scope of the current study. Finally, we have added inserts to the photomicrographs to highlight the overlay between GFP and TRPA1 signals.

> Text
>
> The manuscript includes a number of absolute statement, such as \"... spatial spread of hypoxia-evoked TRPA1 sparklets were identical to those of....\", \"... NOX inhibitor apocynin had no effect....\", etc. \"Identical\" and \"no\" simply do no exist in experimental evidence. Such statements must be presented in statistical terms, such as your use of \"... significantly diminished....\" with reference to data with error bars.

As per the Review Editor's suggestion, we now describe our findings in terms of statistical significant differences. "Absolute" terms were used in the initial manuscript to improve readability.
